Monographs

Theramine™
reference
Sentra Am™
reference
Sentra PM™
reference
AppTrim™
reference
Pulmona™
reference
AppTrimD™
Hypertensa™

Disease Condition
Monographs

Fibromyalgia
reference

Fibromyalgia Reference List

1.Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother. 2002;36:440-443.

2.Albers JW, Berent S. Controversies in neurotoxicology: current status. Neurol Clin. 2000;18:741-764.

3.Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-3483.

4.Castoldi AF, Coccini T, Manzo L. Biological markers of neurotoxic diseases. Funct Neurol. 2001;16 Suppl 4:39-44.

5.Chouaniere D, Wild P, Fontana JM et al. Neurobehavioral disturbances arising from occupational toluene exposure. Am J Ind Med. 2002;41:77-88.

6.Choudhary S, Raheja G, Gupta V et al. Possible involvement of dopaminergic neurotransmitter system in dichlorvos induced delayed neurotoxicity. J Biochem Mol Biol Biophys. 2002;6:29-36.

7.Citak A, Kaya O, Ucsel R et al. Acute isoniazid neurotoxicity in childhood. Turk J Pediatr. 2002;44:54-57.

8.Cooper CL, Jeohn GH, Tobias P et al. Serum-dependence of LPS-induced neurotoxicity in rat cortical neurons. Ann N Y Acad Sci. 2002;962:306-317.

9.Fukuda T. Neurotoxicity of MPTP. Neuropathology. 2001;21:323-332.

10.Galvan-Arzate S, Santamaria A. Neurotoxicity of diethylpropion: neurochemical and behavioral findings in rats. Ann N Y Acad Sci. 2002;965:214-224.

11.Gunasekar PG, Mickova V, Kotyzova D et al. Role of astrocytes in trimethyltin neurotoxicity. J Biochem Mol Toxicol. 2001;15:256-262.

12.Guo-Ross SX, Clark S, Montoya DA et al. Prenatal choline supplementation protects against postnatal neurotoxicity.

13.Hazell AS. Astrocytes and manganese neurotoxicity. Neurochem Int. 2002;41:271-277.

14.Imam SZ, Newport GD, Duhart HM et al. Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells. Ann N Y Acad Sci. 2002;965:204-213.

15.James CW, McNelis KC, Matalia MD et al. Central nervous system toxicity and amprenavir oral solution. Ann Pharmacother. 2002;36:174.

16.Kawahara M, Kato-Negishi M, Kuroda Y. Pyruvate blocks zinc-induced neurotoxicity in immortalized hypothalamic neurons. Cell Mol Neurobiol. 2002;22:87-93.

17.Meyer JS, Ali SF. Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Ann N Y Acad Sci. 2002;965:373-380.

18.Obrocki J, Schmoldt A, Buchert R et al. Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett. 2002;127:285-297.

19.Olney JW, Wozniak DF, Farber NB et al. The enigma of fetal alcohol neurotoxicity. Ann Med. 2002;34:109-119.

20.Othieno-Abinya NA, Nyabola LO. Experience with vincristine--associated neurotoxicity. East Afr Med J. 2001;78:376-378.

21.Pandeya SN, Sriram D, Yogeeswari P et al. Anticonvulsant and neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives. Pharmazie. 2001;56:875-876.

22.Ramassamy C, Clostre F, Christen Y et al. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol. 1990;42:785-789.

23.Rodnitzky RL. Drug-induced movement disorders. Clin Neuropharmacol. 2002;25:142-152.

24.Stein J, Schettler T, Wallinga D et al. In harm's way: toxic threats to child development. J Dev Behav Pediatr. 2002;23:S13-S22.

25.Szutowicz A. Aluminum, NO, and nerve growth factor neurotoxicity in cholinergic neurons.

26.Tikka TM, Vartiainen NE, Goldsteins G et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain. 2002;125:722-731.

27.Wallace KB. Mechanisms of pyrethroid neurotoxicity: implications for cumulative risk assessment. Toxicology. 2002;171:1.

28.Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 2002;59:553-558.

29.Andrich J, Schmitz T, Saft C et al. Autonomic nervous system function in Huntington's disease. J Neurol Neurosurg Psychiatry. 2002;72:726-731.

30.Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol. 2002;9:195-199.

31.Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab. 2001;281:E1115-E1121.

32.Cuny E, Richer E, Castel JP. Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal Baclofen therapy. Brain Inj. 2001;15:917-925.

33.Kitae S, Murata Y, Tachiki N et al. Assessment of cardiovascular autonomic dysfunction in multiple system atrophy. Clin Auton Res. 2001;11:39-44.

34.Lachenecker P, Reiners K, Krauser M et al. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler. 2001;7:327-334.

35.Merkelbach S, Dillmann U, Kolmel C et al. Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis. Mult Scler. 2001;7:320-326.

36.Omboni S, Smit AA, van Lieshout JJ et al. Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure. Clin Sci (Lond). 2001;101:609-618.

37.Turuspekova ST. [Autonomic regulation disorders caused by low dose ionizing irradiation]. Voen Med Zh. 2001;322:45-50.

38.Wichter T, Matheja P, Eckardt L et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702-706.

39.Buskila D, Press J. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue. Best Pract Res Clin Rheumatol. 2001;15:747-758.

40.Carmona L. More evidence on the dysautonomic nature of fibromyalgia: the association with short stature. Arthritis Rheum. 2002;46:1415-1416.

41.Cohen H, Neumann L, Shore M et al. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum. 2000;29:217-227.

42.Cohen H, Neumann L, Kotler M et al. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Isr Med Assoc J. 2001;3:755-760.

43.Holman AJ. Is hypermobility a factor in fibromyalgia? J Rheumatol. 2002;29:396-398.

44.Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum. 2000;29:197-199.

45.Raj SR, Brouillard D, Simpson CS et al. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol. 2000;27:2660-2665.

46.Samborski W, Stratz T, Kretzmann WM et al. [Comparative studies of the incidence of vegetative and functional disorders in backache and generalized tendomyopathies]. Z Rheumatol. 1991;50:378-381.

47.Haley RW, Vongpatanasin W, Wolfe GI et al. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. Am J Med. 2004;117:469-478.

48.van de BP. Cardiac autonomic dysfunction in Gulf War syndrome: veterans' hearts don't rest at night. Am J Med. 2004;117:531-532.

49.Chelimsky G, Chelimsky T. Familial association of autonomic and gastrointestinal symptoms. Clin Auton Res. 2001;11:383-386.

50.Cohen H, Loewenthal U, Matar M et al. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167-171.

51.Deriagina LE, Zashikhina VV, Ruvinova LG et al. [Autonomic nervous system regulation of cardiac rhythm and psychophysiologic state of individuals working with wood antiseptics]. Med Tr Prom Ekol. 2001;13-18.

52.Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62 Suppl 21:11-14.

53.Ueda N, Nakamura J. [Side effects and its countermeasures of antidepressant]. Nippon Rinsho. 2001;59:1535-1538.

54.Wu ML, Deng JF, Tsai WJ et al. Food poisoning due to methamidophos-contaminated vegetables. J Toxicol Clin Toxicol. 2001;39:333-336.

55.Yamanaka S, Fujita I, Murota T et al. [Cholinergic crisis following administration of distigmine bromide: a case report]. Hinyokika Kiyo. 2002;48:21-23.

56.Recommended health-based limits in ocupational exposure to heavy metals. Report of a WHO study group. World Health Organ Tech Rep Ser. 1980;647:1-116.

57.Anawar HM, Akai J, Mostofa KM et al. Arsenic poisoning in groundwater: health risk and geochemical sources in Bangladesh. Environ Int. 2002;27:597-604.

58.Antonio MT, Corredor L, Leret ML. Study of the activity of several brain enzymes like markers of the neurotoxicity induced by perinatal exposure to lead and/or cadmium. Toxicol Lett. 2003;143:331-340.

59.Arroyo HA. [Toxic encephalopathies]. Rev Neurol. 2004;38:1083-1089.

60.Aschner M. Astrocyte metallothioneins (MTs) and their neuroprotective role. Ann N Y Acad Sci. 1997;825:334-347.

61.Bar-Sela S, Reingold S, Richter ED. Amyotrophic lateral sclerosis in a battery-factory worker exposed to cadmium. Int J Occup Environ Health. 2001;7:109-112.

62.Caldwell BK, Caldwell JC, Mitra SN et al. Searching for an optimum solution to the Bangladesh arsenic crisis. Soc Sci Med. 2003;56:2089-2096.

63.Cano JR, Catalan B, Jara C. [Neuronopathy due to cisplatin]. Rev Neurol. 1998;27:606-610.

64.Cattaneo MT, Filipazzi V, Piazza E et al. Transient blindness and seizure associated with cisplatin therapy. J Cancer Res Clin Oncol. 1988;114:528-530.

65.Chisolm JJ, Jr. Poisoning due to heavy metals. Pediatr Clin North Am. 1970;17:591-615.

66.Ernst E, Thompson CJ. Heavy metals in traditional Chinese medicines: a systematic review. Clin Pharmacol Ther. 2001;70:497-504.

67.Fountain SB, Teyler TJ. Characterizing neurotoxicity using the in vitro hippocampal brain slice preparation: heavy metals. Prog Clin Biol Res. 1987;253:19-31.

68.Graeme KA, Pollack CV, Jr. Heavy metal toxicity, Part I: arsenic and mercury. J Emerg Med. 1998;16:45-56.

69.Greenhouse AH. Heavy metals and the nervous system. Clin Neuropharmacol. 1982;5:45-92.

70.Gupta BN, Mathur AK. Toxicity of heavy metals (a review). Indian J Med Sci. 1983;37:236-240.

71.Huttunen J. [Persian Gulf war syndrome, amalgam and silicone implants, chemical poisoning or psychosomatic syndrome?]. Duodecim. 2004;120:496-498.

72.Krantz A, Dorevitch S. Metal exposure and common chronic diseases: a guide for the clinician. Dis Mon. 2004;50:220-262.

73.Lloyd P. Invisible killers: heavy metals, saturnine envy, and the tragic death of Raphaelle Peale. Trans Stud Coll Physicians Phila. 1994;16:83-99.

74.Montgomery EB, Jr. Heavy metals and the etiology of Parkinson's disease and other movement disorders. Toxicology. 1995;97:3-9.

75.O'Donoghue JL, Nasr AN, Raleigh RL. Toxic neuropathy--an overview. J Occup Med. 1977;19:379-382.

76.Oller A, Bates H. Metals in perspective. J Environ Monit. 2004;6:74N.

77.Patrick L. Toxic metals and antioxidants: Part II. The role of antioxidants in arsenic and cadmium toxicity. Altern Med Rev. 2003;8:106-128.

78.Quig D. Cysteine metabolism and metal toxicity. Altern Med Rev. 1998;3:262-270.

79.Rusyniak DE. Pearls and pitfalls in the approach to patients with neurotoxic syndromes. Semin Neurol. 2001;21:407-416.

80.Damodaran TV, Mecklai AA, Abou-Donia MB. Sarin causes altered time course of mRNA expression of alpha tubulin in the central nervous system of rats. Neurochem Res. 2002;27:177-181.

81.Kalra R, Singh SP, Razani-Boroujerdi S et al. Subclinical doses of the nerve gas sarin impair T cell responses through the autonomic nervous system. Toxicol Appl Pharmacol. 2002;184:82-87.

82.Roberts J. US responds to new suggestion of Gulf War syndrome. BMJ. 1996;312:1629.

83.Bernard M, Rosef A, Hernandez LM et al. Gulf War Veterans Treating Symptoms and Syndromes. National Academy Press, 2001.

84.Hilsted J, Low P. Diabetic Autonomic Neuropathy. Clinical Automonic Disorders. Lippincott-Raven Publishers, 1997: 487-507.

85.Low P, Mcleod JG. Autonomic Neuropathies. In: Low P, editor. Clinical Autonomic Disorders. Lippincott-Ravin Publishers, 1997: 463-486.

86.Gracely RH, Petzke F, Wolf JM et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343.

87.Vestergaard-Poulsen P, Thomsen C, Norregaard J et al. 31P NMR spectroscopy and electromyography during exercise and recovery in patients with fibromyalgia. J Rheumatol. 1995;22:1544-1551.

88.Agelink MW, Majewski TB, Andrich J et al. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med. 2002;30:997-1006.

89.Ahern GL, Sollers JJ, Lane RD et al. Heart rate and heart rate variability changes in the intracarotid sodium amobarbital test. Epilepsia. 2001;42:912-921.

90.Bazhenova OV, Plonskaia O, Porges SW. Vagal reactivity and affective adjustment in infants during interaction challenges. Child Dev. 2001;72:1314-1326.

91.Behrens S, Franz MR. Circadian variation of arrhythmic events, electrophysiological properties, and the autonomic nervous system. Eur Heart J. 2001;22:2144-2146.

92.Brownley KA, Milanovich JR, Motivala SJ et al. Autonomic and cardiovascular function in HIV spectrum disease: early indications of cardiac pathophysiology. Clin Auton Res. 2001;11:319-326.

93.Bul'on VV, Zavodskaia IS, Khnychenko LK. [The effect of neurotropic agents on lipid peroxidation in the heart and stomach with neurogenic lesions]. Eksp Klin Farmakol. 1994;57:18-20.

94.Censi F, Calcagnini G, Bartolini P et al. Spontaneous and forced non-linear oscillations in heart period: role of the sino-atrial node. Med Eng Phys. 2002;24:61-69.

95.De Vito G, Galloway SD, Nimmo MA et al. Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans. Clin Physiol Funct Imaging. 2002;22:32-38.

96.Delahaye N, Le Guludec D, Dinanian S et al. Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy. Circulation. 2001;104:2911-2916.

97.Druschky A, Hilz MJ, Hopp P et al. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [(123)I]metaiodobenzylguanidine-SPECT. Brain. 2001;124:2372-2382.

98.El Mas MM, Afify EA, Mohy El-Din MM et al. Testosterone facilitates the baroreceptor control of reflex bradycardia: role of cardiac sympathetic and parasympathetic components. J Cardiovasc Pharmacol. 2001;38:754-763.

99.Ellenby MS, McNames J, Lai S et al. Uncoupling and recoupling of autonomic regulation of the heart beat in pediatric septic shock. Shock. 2001;16:274-277.

100.Favret F, Henderson KK, Clancy RL et al. Exercise training alters the effect of chronic hypoxia on myocardial adrenergic and muscarinic receptor number. J Appl Physiol. 2001;91:1283-1288.

101.Flachenecker P, Toyka KV, Reiners K. [Cardiac arrhythmias in Guillain-Barre syndrome. An overview of the diagnosis of a rare but potentially life-threatening complication]. Nervenarzt. 2001;72:610-617.

102.Flanagan DE, Pratt E, Murphy J et al. Alcohol consumption alters insulin secretion and cardiac autonomic activity. Eur J Clin Invest. 2002;32:187-192.

103.Furlan R, Jacob G, Palazzolo L et al. Sequential modulation of cardiac autonomic control induced by cardiopulmonary and arterial baroreflex mechanisms. Circulation. 2001;104:2932-2937.

104.Galoyan A, Srapionian R, Arora RC et al. Responsiveness of intrinsic cardiac neurons to left atrial and hypothalamic cardioactive peptides. Auton Neurosci. 2001;92:11-20.

105.Ghuran AV, Camm AJ. Ischaemic heart disease presenting as arrhythmias. Br Med Bull. 2001;59:193-210.

106.Gianaros PJ, Quigley KS, Mordkoff JT et al. Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors. Psychophysiology. 2001;38:642-652.

107.Goldstein DS, Holmes CS, Dendi R et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology. 2002;58:1247-1255.

108.Guerra LB, Andrade LO, Galvao LM et al. Cyclophosphamide-induced immunosuppression protects cardiac noradrenergic nerve terminals from damage by Trypanosoma cruzi infection in adult rats. Trans R Soc Trop Med Hyg. 2001;95:505-509.

109.Harris AS, Burgess HJ, Dawson D. The effects of day-time exogenous melatonin administration on cardiac autonomic activity. J Pineal Res. 2001;31:199-205.

110.Hejjel L, Gal I. Heart rate variability analysis. Acta Physiol Hung. 2001;88:219-230.

111.Hemingway H, Malik M, Marmot M. Social and psychosocial influences on sudden cardiac death, ventricular arrhythmia and cardiac autonomic function. Eur Heart J. 2001;22:1082-1101.

112.Hirashima Y, Takashima S, Matsumura N et al. Right sylvian fissure subarachnoid hemorrhage has electrocardiographic consequences. Stroke. 2001;32:2278-2281.

113.Hosova J, Jirkovska A, Boucek P et al. [Parameters of power spectral analysis of heart rate variability for use in clinical evaluation of various stages of diabetic cardiovascular autonomic neuropathy]. Vnitr Lek. 2001;47:682-688.

114.Hundley BW, Sica AL, Gootman PM. Rhythmicities in sympathetic discharge: a signal of cardiorespiratory integration in developing animals. Ann N Y Acad Sci. 2001;940:416-430.

115.Jones PP, Shapiro LF, Keisling GA et al. Altered autonomic support of arterial blood pressure with age in healthy men. Circulation. 2001;104:2424-2429.

116.Julu PO, Kerr AM, Apartopoulos F et al. Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child. 2001;85:29-37.

117.Kalisnik JM, Avbelj V, Trobec R et al. Imaging of power spectral heart rate variability regarding subject position. Pflugers Arch. 2001;442:R142-R144.

118.Kaminaga T, Matsumura K, Hatanaka H et al. Abnormality of the myocardial sympathetic nervous system in a patient with Becker muscular dystrophy detected with iodine-123 metaiodobenzylguanidine scintigraphy. Clin Nucl Med. 2001;26:701-703.

119.Korneev AA, Sheveleva GA. [The use of the perfused rat heart as a model for selecting antihypoxic compounds]. Farmakol Toksikol. 1991;54:67-70.

120.Kottferova J, Korenekova B. The effect of emissions on heavy metals concentrations in cattle from the area of an industrial plant in Slovakia. Arch Environ Contam Toxicol. 1995;29:400-405.

121.Kriatselis HD, Goehl K, Richter P et al. Radiofrequency energy modification of the atrioventricular junction in patients with atrial fibrillation: modes of ventricular response under autonomic blockade and long-term effect. Pacing Clin Electrophysiol. 2001;24:1312-1320.

122.Kucukhuseyin C, Akbas N, Yillar DO. Effect of ondansetron on the contractile responses to positive inotropic agents in electrically driven left atria of rats. J Basic Clin Physiol Pharmacol. 2001;12:271-287.

123.Langewitz W, Ruddel H, Schachinger H et al. Changes in sympathetic and parasympathetic cardiac activation during mental load: an assessment by spectral analysis of heart rate variability. Homeost Health Dis. 1991;33:23-33.

124.Lomtadze DM, Tsorin IB, Chirkova EI et al. [The absence of a parallelism between the antihypoxic and anti-ischemic actions of pharmacological agents]. Farmakol Toksikol. 1991;54:27-29.

125.Lomtadze DM, Tsorin IB, Chirkova EI et al. [The protective action on the myocardium of antihypoxants in acute occlusion and subsequent reperfusion of the coronary artery]. Farmakol Toksikol. 1990;53:31-34.

126.Malfatto G, Branzi G, Riva B et al. Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure. Eur J Heart Fail. 2002;4:159-166.

127.Maroko PR, Libby P, Ginks WR et al. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest. 1972;51:2710-2716.

128.Meissner A, Eckardt L, Kirchhof P et al. Effects of thoracic epidural anesthesia with and without autonomic nervous system blockade on cardiac monophasic action potentials and effective refractoriness in awake dogs. Anesthesiology. 2001;95:132-138.

129.Mukkamala R, Cohen RJ. A forward model-based validation of cardiovascular system identification. Am J Physiol Heart Circ Physiol. 2001;281:H2714-H2730.

130.Musaeva ZA, Khaspekova NB, Vein AM. [Variability of heart rhythm in dynamic study of the psychovegetative relationship in neurogenic syncope]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2001;51:749-751.

131.Myslivecek J. [Current views on receptors for mediators of the autonomic nervous system of the heart]. Cas Lek Cesk. 2001;140:423-426.

132.Nault MA, Milne B, Parlow JL. Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. Anesthesiology. 2002;96:336-341.

133.Nozdrachev AD, Shcherbatykh I. [Current methods of evaluation of functional status of the autonomic nervous system]. Fiziol Cheloveka. 2001;27:95-101.

134.Oyama N, Oyama N, Yokoshiki H et al. Iodine-123-metaiodobenzylguanidine scintigraphy of total cardiac adrenergic denervation in Brugada syndrome. Jpn Heart J. 2002;43:183-186.

135.Paterson D. Nitric oxide and the autonomic regulation of cardiac excitability. The G.L. Brown Prize Lecture. Exp Physiol. 2001;86:1-12.

136.Perkiomaki JS, Zareba W, Couderc JP et al. Heart rate variability in patients with congenital long QT syndrome. Ann Noninvasive Electrocardiol. 2001;6:298-304.

137.Petretta M, Bonaduce D, Spinelli L et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145:691-696.

138.Ackerman RH, Correia JA, Alpert NM et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiologic correlations. Arch Neurol. 1981;38:537-543.

139.Ackerman RH, Alpert NM, Correia JA et al. Positron imaging in ischemic stroke disease. Ann Neurol. 1984;15 Suppl:S126-S130.

140.Ackerman RH, Subramanyam R, Correia JA et al. Positron imaging of cerebral blood flow during continuous inhalation of C15O2. Stroke. 1980;11:45-49.

141.Adler CM, Malhotra AK, Elman I et al. Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia. Neuropsychopharmacology. 2002;26:295-300.

142.Cranston I, Reed LJ, Marsden PK et al. Changes in regional brain (18)F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure. Diabetes. 2001;50:2329-2336.

143.Cumming P, Leger GC, Kuwabara H et al. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. J Cereb Blood Flow Metab. 1993;13:668-675.

144.DeGrado TR, Baldwin SW, Wang S et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805-1814.

145.Eustache F, Rioux P, Desgranges B et al. Healthy aging, memory subsystems and regional cerebral oxygen consumption. Neuropsychologia. 1995;33:867-887.

146.Evans AC, Marrett S, Neelin P et al. Anatomical mapping of functional activation in stereotactic coordinate space. Neuroimage. 1992;1:43-53.

147.Finklestein S, Alpert NM, Ackerman RH et al. Positron imaging of the normal brain--regional patterns of cerebral blood flow and metabolism. Trans Am Neurol Assoc. 1980;105:8-10.

148.Flower MA, Ott RJ, Webb S et al. A clinical evaluation of a prototype positron camera for longitudinal emission tomography. Br J Radiol. 1984;57:1103-1117.

149.Friedland RP, Koss E, Lerner A et al. Functional imaging, the frontal lobes, and dementia. Dementia. 1993;4:192-203.

150.Friedland RP, Koss E, Lerner A et al. Functional imaging, the frontal lobes, and dementia. Dementia. 1993;4:192-203.

151.Friedland RP, Mathis CA, Budinger TF et al. Labeled choline and phosphorylcholine: body distribution and brain autoradiography: concise communication. J Nucl Med. 1983;24:812-815.

152.Friedland RP. Positron imaging in dementing illnesses. J Neuropsychiatry Clin Neurosci. 1989;1:S56-S60.

153.Fujita H, Meyer E, Reutens DC et al. Cerebral [15O] water clearance in humans determined by positron emission tomography: II. Vascular responses to vibrotactile stimulation. J Cereb Blood Flow Metab. 1997;17:73-79.

154.Gjedde A, Kuwabara H. Absent recruitment of capillaries in brain tissue recovering from stroke. Acta Neurochir Suppl (Wien ). 1993;57:35-40.

155.Gjedde A, Reith J, Dyve S et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A. 1991;88:2721-2725.

156.Hara T. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med. 2001;42:1815-1817.

157.Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187-199.

158.Heiss WD, Szelies B, Kessler J et al. Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann N Y Acad Sci. 1991;640:65-71.

159.Hoshi H, Kuwabara H, Leger G et al. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab. 1993;13:57-69.

160.Kessler J, Thiel A, Karbe H et al. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke. 2000;31:2112-2116.

161.Kotzerke J, Gschwend JE, Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med. 2002;43:200-202.

162.Kuwabara H, Ohta S, Brust P et al. Density of perfused capillaries in living human brain during functional activation. Prog Brain Res. 1992;91:209-215.

163.Kuwabara H, Cumming P, Reith J et al. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab. 1993;13:43-56.

164.Kuwabara H, Gjedde A. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate. J Nucl Med. 1991;32:692-698.

165.Levine RL. The study of cerebral ischemic reversibility: Part I. A review of positron imaging studies. Am J Physiol Imaging. 1986;1:54-58.

166.McGeer PL, McGeer EG, Kamo H et al. Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:501-518.

167.Meyer E, Ferguson SS, Zatorre RJ et al. Attention modulates somatosensory cerebral blood flow response to vibrotactile stimulation as measured by positron emission tomography. Ann Neurol. 1991;29:440-443.

168.Meyer MA. Elevated basal ganglia glucose metabolism in cyclosporine neurotoxicity: a positron emission tomography imaging study. J Neuroimaging. 2002;12:92-93.

169.Muenter MD, Forno LS, Hornykiewicz O et al. Hereditary form of parkinsonism--dementia. Ann Neurol. 1998;43:768-781.

170.Obrocki J, Schmoldt A, Buchert R et al. Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett. 2002;127:285-297.

171.Ohta S, Meyer E, Fujita H et al. Cerebral [15O]water clearance in humans determined by PET: I. Theory and normal values. J Cereb Blood Flow Metab. 1996;16:765-780.

172.Ohta S, Meyer E, Thompson CJ et al. Oxygen consumption of the living human brain measured after a single inhalation of positron emitting oxygen. J Cereb Blood Flow Metab. 1992;12:179-192.

173.Paans AM, Vaalburg W, Woldring MG. A rotating double-headed positron camera. J Nucl Med. 1985;26:1466-1471.

174.Picchio M, Landoni C, Messa C et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol. 2002;179:482-484.

175.Pieterman RM, Que TH, Elsinga PH et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer.

176.Pietila M, Malminiemi K, Vesalainen R et al. Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. J Nucl Med. 2002;43:773-779.

177.Price DT, Coleman RE, Liao RP et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273-280.

178.Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol. 2001;28:541-559.

179.Rajeswaran S, Hume SP, Cremer JE et al. Dynamic monitoring of [11C]diprenorphine in rat brain using a prototype positron imaging device. J Neurosci Methods. 1991;40:223-232.

180.Reutens DC, McHugh MD, Toussaint PJ et al. L-arginine infusion increases basal but not activated cerebral blood flow in humans. J Cereb Blood Flow Metab. 1997;17:309-315.

181.Reutens DC, Gjedde AH, Meyer E. Regional lumped constant differences and asymmetry in fluorine-18-FDG uptake in temporal lobe epilepsy. J Nucl Med. 1998;39:176-180.

182.Schnell O. [Scintigraphic assessment of blood flow regulation and sympathetic function of the diabetic heart]. Dtsch Med Wochenschr. 2002;127:965-970.

183.Strafella AP, Paus T, Barrett J et al. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21:RC157.

184.Szabo Z, McCann UD, Wilson AA et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med. 2002;43:678-692.

185.Talbot JN, Haioun C, Rain JD et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol. 2001;38:193-221.

186.Tamura K, Yoshikawa K, Tsujii H et al. [Diagnosis of esophageal cancer using positron emission tomography]. Nippon Geka Gakkai Zasshi. 2002;103:325-330.

187.Aarflot T, Bruusgaard D. Association between chronic widespread musculoskeletal complaints and thyroid autoimmunity. Results from a community survey. Scand J Prim Health Care. 1996;14:111-115.

188.Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep. 2002;6:289-298.

189.Alnigenis MN, Barland P. Fibromyalgia syndrome and serotonin. Clin Exp Rheumatol. 2001;19:205-210.

190.Anderberg UM. [Stress can induce neuroendocrine disorders and pain]. Lakartidningen. 1999;96:5497-5499.

191.Anderberg UM, Liu Z, Berglund L et al. Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol. 1998;57 Suppl 2:77-80.

192.Bengtsson A, Henriksson KG. The muscle in fibromyalgia--a review of Swedish studies. J Rheumatol Suppl. 1989;19:144-149.

193.Bennett RM. Fibromyalgia and the facts. Sense or nonsense. Rheum Dis Clin North Am. 1993;19:45-59.

194.Bradley LA, McKendree-Smith NL, Alarcon GS. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain. 2000;4:148-157.

195.Carette S. Fibromyalgia 20 years later: what have we really accomplished? J Rheumatol. 1995;22:590-594.

196.Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4:134-153.

197.Clauw DJ. Potential mechanisms in chemical intolerance and related conditions. Ann N Y Acad Sci. 2001;933:235-253.

198.Cook DB, Lange G, Ciccone DS et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364-378.

199.Goldstein JA. Fibromyalgia syndrome: a pain modulation disorder related to altered limbic function? Baillieres Clin Rheumatol. 1994;8:777-800.

200.Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998;315:367-376.

201.Houvenagel E. Mechanisms of pain in fibromyalgia. Rev Rhum Engl Ed. 1999;66:97-101.

202.Klein R, Berg PA. Diagnostic relevance of antibodies to serotonin and phospholipids in fibromyalgia syndrome. J Rheumatol. 2002;29:395-396.

203.Kravis MM, Munk PL, McCain GA et al. MR imaging of muscle and tender points in fibromyalgia. J Magn Reson Imaging. 1993;3:669-670.

204.Maliszewski AM, Goldenberg DL, Hurwitz S et al. Regulation of the renin-angiotensin-aldosterone system in fibromyalgia. J Rheumatol. 2002;29:1482-1487.

205.Martinez-Lavin M, Arechiga H, Schmulson M et al. [Frequent clinical syndromes without anatomical bases. New perspectives on fibromyalgia and irritable intestine]. Gac Med Mex. 2002;138:41-56.

206.Neeck G. Pathogenic mechanisms of fibromyalgia. Ageing Res Rev. 2002;1:243-255.

207.Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001;31:1331-1345.

208.Russell IJ. Is fibromyalgia a distinct clinical entity? The clinical investigator's evidence. Baillieres Best Pract Res Clin Rheumatol. 1999;13:445-454.

209.van West D, Maes M. Neuroendocrine and immune aspects of fibromyalgia. BioDrugs. 2001;15:521-531.

210.Wortmann RL. Searching for the cause of fibromyalgia: is there a defect in energy metabolism? Arthritis Rheum. 1994;37:790-793.

211.Kornilova LN, Solov'eva AD, Oknin VY et al. Effect of the character of autonomic response and the emotional and personality features of a human being on reactions of the vestibular system. Hum Physiol. 1999;25:549-554.

212.Carney RM, Blumenthal JA, Stein PK et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104:2024-2028.

213.Karpyak VM, Rasmussen KG, Hammill SC et al. Changes in heart rate variability in response to treatment with electroconvulsive therapy. J ECT. 2004;20:81-88.

214.Nahshoni E, Aravot D, Aizenberg D et al. Heart rate variability in patients with major depression. Psychosomatics. 2004;45:129-134.

215.Bar KJ, Greiner W, Jochum T et al. The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord. 2004;82:245-252.

216.Robert JJ, Orr WC, Elsenbruch S. Modulation of sleep quality and autonomic functioning by symptoms of depression in women with irritable bowel syndrome. Dig Dis Sci. 2004;49:1250-1258.

217.Haley RW. Gulf syndrome research has passed peer review. Nature. 2001;410:739.

218.Haley RW. Will we solve the Gulf War syndrome puzzle by population surveys or clinical research. Am J Med. 2000;109:744-748.

219.Haley RW. Re: "Factor analysis of self-reported symptoms: does it identify a Gulf War syndrome?". Am J Epidemiol. 2000;152:1204-1206.

220.Haley RW, Fleckenstein JL, Marshall WW et al. Effect of basal ganglia injury on central dopamine activity in Gulf War syndrome: correlation of proton magnetic resonance spectroscopy and plasma homovanillic acid levels. Arch Neurol. 2000;57:1280-1285.

221.Haley RW, Marshall WW, McDonald GG et al. Brain abnormalities in Gulf War syndrome: evaluation with 1H MR spectroscopy. Radiology. 2000;215:807-817.

222.Haley RW. PON1 and low-dose sarin in marmosets. J Psychopharmacol. 2000;14:87-88.

223.Roland PS, Haley RW, Yellin W et al. Vestibular dysfunction in Gulf War syndrome. Otolaryngol Head Neck Surg. 2000;122:319-329.

224.Haley RW. Is there a Gulf War syndrome? Lancet. 1999;354:1645-1646.

225.Haley RW. Chronic multisystem illness among Gulf War veterans. JAMA. 1999;282:327-329.

226.Haley RW. Point: bias from the "healthy-warrior effect" and unequal follow-up in three government studies of health effects of the Gulf War. Am J Epidemiol. 1998;148:315-323.

227.Haley RW. Is Gulf War syndrome due to stress? The evidence reexamined. Am J Epidemiol. 1997;146:695-703.

228.Haley RW, Kurt TL. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. JAMA. 1997;277:231-237.

229.Haley RW, Hom J, Roland PS et al. Evaluation of neurologic function in Gulf War veterans. A blinded case-control study. JAMA. 1997;277:223-230.

230.Haley RW, Kurt TL, Hom J. Is there a Gulf War Syndrome? Searching for syndromes by factor analysis of symptoms. JAMA. 1997;277:215-222.

231.Haley RW. The scientific basis for using surveillance and risk factor data to reduce nosocomial infection rates. J Hosp Infect. 1995;30 Suppl:3-14.

232.Haley R, Shropshire S, Markand ON et al. Clinico-pathologic conference. Tex Med. 1970;66:82-92.

233.Haley RW, Vongpatanasin W, Wolfe GI et al. Blunted circadian variation in autonomic regulation of sinus node function in veterans with Gulf War syndrome. Am J Med. 2004;117:469-478.

234.Binns J, Cherry N, Golomb B, Haley RW, Steele L. Scientific Progress in Understanding Gulf War Veterans Illnesses: Report and Recommendations.  2004.  Veterans Administration. Research Advisory Committee on Gulf War Veterans' Illnesses.

Ref Type: Report

235.Carnall D. Britain investigates Gulf war syndrome. BMJ. 1996;312:332-333.

236.Currie E. The Gulf War syndrome. BMJ. 1995;310:1334-1335.

237.Haley RW. Is Gulf War syndrome due to stress? The evidence reexamined. Am J Epidemiol. 1997;146:695-703.

238.Haley RW, Kurt TL, Hom J. Is there a Gulf War Syndrome? Searching for syndromes by factor analysis of symptoms. JAMA. 1997;277:215-222.

239.Haley RW. Is there a Gulf War syndrome? Lancet. 1999;354:1645-1646.

240.Haley RW. Re: "Factor analysis of self-reported symptoms: does it identify a Gulf War syndrome?". Am J Epidemiol. 2000;152:1204-1206.

241.Haley RW, Fleckenstein JL, Marshall WW et al. Effect of basal ganglia injury on central dopamine activity in Gulf War syndrome: correlation of proton magnetic resonance spectroscopy and plasma homovanillic acid levels. Arch Neurol. 2000;57:1280-1285.

242.Haley RW, Luk GD, Petty F. Use of structural equation modeling to test the construct validity of a case definition of Gulf War syndrome: invariance over developmental and validation samples, service branches and publicity. Psychiatry Res. 2001;102:175-200.

243.Haley RW. Gulf war syndrome: narrowing the possibilities. Lancet Neurol. 2003;2:272-273.

244.Jamal GA, Hansen S, Apartopoulos F et al. The "Gulf War syndrome". Is there evidence of dysfunction in the nervous system? J Neurol Neurosurg Psychiatry. 1996;60:449-451.

245.Lotti M, Moretto A. Cholinergic symptoms and Gulf War syndrome. Nat Med. 1995;1:1225-1226.

246.Pennisi E. Chemicals behind Gulf War syndrome? Science. 1996;272:479-480.

247.Roberts J. New US theory on Gulf war syndrome. BMJ. 1996;312:1058.

248.Aalto J, Kiianmaa K. Role of brain monoaminergic systems in the increased ethanol drinking caused by REM-sleep deprivation. Alcohol Alcohol. 1987;Suppl 1:313-317.

249.Adell A, Celada P, Abellan MT et al. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res Brain Res Rev. 2002;39:154-180.

250.Adrien J, Tissier MH, Lanfumey L et al. Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat. Neuropharmacology. 1992;31:519-529.

251.Adrien J, Laguzzi R, Bourgoin S et al. [Sleep in the rate following raphe lesion: pharmacology of the serotonin system]. Waking Sleeping. 1980;4:119-129.

252.Adrien J. Ontogenesis of some sleep regulations: early postnatal impairment of the monoaminergic systems. Prog Brain Res. 1978;48:393-405.

253.Adrien J. [Sleep organisation in the kitten following early lesions to the structures involved in the regulation of alertness (author's transl)]. Rev Electroencephalogr Neurophysiol Clin. 1977;7:278-283.

254.Adrien J, Bourgoin S, Hamon M. Midbrain raphe lesion in the newborn rat I. Neurophysiological aspects of sleep. Brain Res. 1977;127:99-110.

255.Albert R, Merz A, Schubert J et al. [Sleep deprivation and subsequent sleep phase advance stabilizes the positive effect of sleep deprivation in depressive episodes]. Nervenarzt. 1998;69:66-69.

256.Arita H, Ichikawa K, Sakamoto M. Serotonergic cells in nucleus raphe pallidus provide tonic drive to posterior cricoarytenoid motoneurons via 5-hydroxytryptamine2 receptors in cats. Neurosci Lett. 1995;197:113-116.

257.Ashley DV. Dietary control of brain 5-hydroxytryptamine synthesis: implications in the etiology of obesity. Int J Vitam Nutr Res Suppl. 1986;29:27-40.

258.Asikainen M, Toppila J, Alanko L et al. Sleep deprivation increases brain serotonin turnover in the rat. Neuroreport. 1997;8:1577-1582.

259.Barratt ES, Adams PM, Poffenbarger PL et al. Effects of rapid depletion of phenylalanine and tyrosine on sleep and behavior. Pharmacol Biochem Behav. 1976;5:47-53.

260.Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6:101-197.

261.Bjorkum AA, Bjorvatn B, Neckelmann D et al. Sleep effects following intrathecal administration of the 5-HT1A agonist 8-OH-DPAT and the NMDA antagonist AP-5 in rats. Brain Res. 1995;692:251-258.

262.Bjorvatn B, Gronli J, Hamre F et al. Effects of sleep deprivation on extracellular serotonin in hippocampus and frontal cortex of the rat. Neuroscience. 2002;113:323-330.

263.Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. Experientia. 1983;39:551-558.

264.Bobrzynska KJ, Godfrey MH, Mrosovsky N. Serotonergic stimulation and nonphotic phase-shifting in hamsters. Physiol Behav. 1996;59:221-230.

265.Bonard EC. [Tryptophan and serotonin]. Rev Med Suisse Romande. 1987;107:701-702.

266.Borbely AA. [Physiological and pharmacological study of the regulation of sleep in rats]. Actual Pharmacol (Paris). 1981;33:91-104.

267.Borbely AA. Effects of light on sleep and activity rhythms. Prog Neurobiol. 1978;10:1-31.

268.Bouhuys AL, Van Den Hoofdakker RH. Effects of midbrain raphe destruction on sleep and locomotor activity in rats. Physiol Behav. 1977;19:535-541.

269.Brown DW. Abnormal fluctuations of acetylcholine and serotonin. Med Hypotheses. 1993;40:309-310.

270.Bucci L. Migraine, insomnia, reactive depression due to brain serotonin deficiency. Br J Psychiatry. 1988;152:867-868.

271.Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. Clin Ter. 1979;91:3-10.

272.Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. Chest. 1999;115:1397-1401.

273.Curzon G. The role and control of brain 5-hydroxytryptamine. Acta Neurol (Napoli). 1977;32:121-131.

274.Drucker-Colin RR, Spanis CW. Is there a sleep transmitter? Prog Neurobiol. 1976;6:1-22.

275.Dugovic C. Role of serotonin in sleep mechanisms. Rev Neurol (Paris). 2001;157:S16-S19.

276.Fenik P, Ogawa H, Veasey SC. Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus and vena cava in the rat. Sleep. 2001;24:871-878.

277.Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. I. Relation to postsynaptic serotonergic stimulation. J Pharmacol Exp Ther. 1983;225:667-674.

278.Guilleminault C. Advances in the pathology of sleep. Electroencephalogr Clin Neurophysiol Suppl. 1978;67-70.

279.Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry. 2000;8:298-306.

280.Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998;315:367-376.

281.Hartmann E. L-tryptophan: a rational hypnotic with clinical potential. Am J Psychiatry. 1977;134:366-370.

282.Hilakivi I. Biogenic amines in the regulation of wakefulness and sleep. Med Biol. 1987;65:97-104.

283.Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. Curr Opin Neurobiol. 1992;2:759-763.

284.Holmes CJ, Jones BE. Importance of cholinergic, GABAergic, serotonergic and other neurons in the medial medullary reticular formation for sleep-wake states studied by cytotoxic lesions in the cat. Neuroscience. 1994;62:1179-1200.

285.Holsboer F. Serotonin and sleep regulation. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:349A-350A.

286.Janzen R, Hunger J. [Causes of sleep disorders from the viewpoint of the neurologist]. Internist (Berl). 1976;17:232-238.

287.Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology. 1999;21:24S-27S.

288.Karnovsky ML. Progress in sleep. N Engl J Med. 1986;315:1026-1028.

289.Kayama Y, Koyama Y. [Brainstem neural mechanisms of sleep and wakefulness]. Nippon Seirigaku Zasshi. 1993;55:1-14.

290.Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. Nippon Rinsho. 1998;56:318-326.

291.Lanoir J, Ternaux JP, Pons C et al. Long-term effects of a tryptophan-free diet on serotonin metabolism and sleep-waking balance in rats. Exp Brain Res. 1981;41:346-357.

292.Leathwood PD. Tryptophan availability and serotonin synthesis. Proc Nutr Soc. 1987;46:143-156.

293.Leathwood PD. Neurotransmitter precursors and brain function. Bibl Nutr Dieta. 1986;54-71.

294.Leonard BE. Serotonin receptors and their function in sleep, anxiety disorders and depression. Psychother Psychosom. 1996;65:66-75.

295.Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. II. Time course of dorsal raphe discharge, PGO waves, and behavioral states. Arch Ital Biol. 1987;126:1-28.

296.Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. I. Long term recordings of dorsal raphe discharge frequency and PGO waves. Arch Ital Biol. 1987;125:317-343.

297.McGinty D, Szymusiak R. The sleep-wake switch: A neuronal alarm clock. Nat Med. 2000;6:510-511.

298.Mendelson WB. Neurotransmitters and sleep. J Clin Psychiatry. 2001;62 Suppl 10:5-8.

299.Morgane PJ. Amine pathways and sleep regulation. Brain Res Bull. 1982;9:743-749.

300.Morgane PJ, Stern WC. The role of serotonin and norepinephrine in sleep-waking activity. Natl Inst Drug Abuse Res Monogr Ser. 1975;37-61.

301.Sallanon M, Janin M, Buda C et al. Serotoninergic mechanisms and sleep rebound. Brain Res. 1983;268:95-104.

302.Wauquier A, Dugovic C. Serotonin and sleep-wakefulness. Ann N Y Acad Sci. 1990;600:447-458.

303.Webb SM. Fibromyalgia and melatonin: are they related? Clin Endocrinol (Oxf). 1998;49:161-162.

304.Wesemann W, Rotsch M, Schulz E et al. Circadian rhythm of serotonin binding in rat brain--II. Influence of sleep deprivation and imipramine. Chronobiol Int. 1986;3:141-146.

305.Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. Adv Biochem Psychopharmacol. 1974;11:133-142.

306.Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science. 1971;173:149-152.

307.Madras BK, Cohen EL, Fernstrom JD et al. Letter: Dietary carbohydrate increases brain tryptophan and decreases free plasma tryptophan. Nature. 1973;244:34-35.

308.Wurtman RJ. When--and why--should nutritional state control neurotransmitter synthesis? J Neural Transm Suppl. 1979;69-79.

309.Wurtman RJ. Nutrients affecting brain composition and behavior. Integr Psychiatry. 1987;5:226-238.

310.Airapetyants MG, Hecht K, Mekhedova AY et al. Effect of intermittent hypokinesia of varied duration on conditioned reflexes, the EEG, and blood neurotransmitter levels in rats. Neurosci Behav Physiol. 1982;12:154-161.

311.Amatruda TT, III, Black DA, McKenna TM et al. Sleep cycle control and cholinergic mechanisms: differential effects of carbachol injections at pontine brain stem sites. Brain Res. 1975;98:501-515.

312.Baust W, Otter HP. Studies on the cholinergic system of the reticular formation. Electroencephalogr Clin Neurophysiol. 1969;27:675.

313.Borsook D, Richardson GS, Moore-Ede MC et al. GABA and circadian timekeeping: implications for manic-depression and sleep disorders. Med Hypotheses. 1986;19:185-198.

314.Bowers MB, Jr., Hartmann EL, Freedman DX. Sleep deprivation and brain acetylcholine. Science. 1966;153:1416-1417.

315.Brown DW. Abnormal fluctuations of acetylcholine and serotonin. Med Hypotheses. 1993;40:309-310.

316.Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. Clin Ter. 1979;91:3-10.

317.Chumakova OV, Liopo AV. Acetylcholinesterase and choline uptake in striatum from rats with varying sleeping times. Alcohol Alcohol. 1996;31:217-220.

318.Cudeiro J, Rivadulla C, Grieve KL. A possible role for nitric oxide at the sleep/wake interface. Sleep. 2000;23:829-835.

319.Datta S, Calvo JM, Quattrochi J et al. Cholinergic microstimulation of the peribrachial nucleus in the cat. I. Immediate and prolonged increases in ponto-geniculo-occipital waves. Arch Ital Biol. 1992;130:263-284.

320.De Souza H, Neto JP. Effects of anti-acetylcholine drugs on aggressive behaviour induced by Cannabis sativa in REM sleep-deprived rats. J Pharm Pharmacol. 1978;30:591-592.

321.Gadea-Ciria M, Stadler H, Lloyd KG et al. Acetylcholine release within the cat striatum during the sleep-wakefulness cycle. Nature. 1973;243:518-519.

322.Gaillard JM. Neurochemical regulation of the states of alertness. Ann Clin Res. 1985;17:175-184.

323.Gillin JC, Mendelson WB, Sitaram N et al. The neuropharmacology of sleep and wakefulness. Annu Rev Pharmacol Toxicol. 1978;18:563-579.

324.Gillin JC, Sitaram N. Rapid eye movement (REM) sleep: cholinergic mechanisms. Psychol Med. 1984;14:501-506.

325.Gillin JC, Mendelson WB, Sitaram N et al. The neuropharmacology of sleep and wakefulness. Annu Rev Pharmacol Toxicol. 1978;18:563-579.

326.Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. Trends Neurosci. 2001;24:237-243.

327.Haranath PS, Venkatakrishna-Bhatt H. Release of acetylcholine from perfused cerebral ventricles in unanaesthetized dogs during waking and sleep. Jpn J Physiol. 1973;23:241-250.

328.Hernandez-Peon R, O'Flaherty JJ, Mazzuchelli O'F. Sleep and other behavioural effects induced by acetylcholinic stimulation of basal temporal cortex and striate structures. Brain Res. 1967;4:243-267.

329.Hilakivi I. Biogenic amines in the regulation of wakefulness and sleep. Med Biol. 1987;65:97-104.

330.Hobson JA, Datta S, Calvo JM et al. Acetylcholine as a brain state modulator: triggering and long-term regulation of REM sleep. Prog Brain Res. 1993;98:389-404.

331.Kayama Y, Koyama Y. Brainstem neural mechanisms of sleep and wakefulness. Eur Urol. 1998;33 Suppl 3:12-15.

332.Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. Experientia. 1984;40:309-338.

333.Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. Nippon Rinsho. 1998;56:318-326.

334.Masserano JM, King C. Effects on sleep of acetylcholine perfusion of the locus coeruleus of cats. Neuropharmacology. 1982;21:1163-1167.

335.McGinty DJ, Drucker-Colin RR. Sleep mechanisms: biology and control of REM sleep. Int Rev Neurobiol. 1982;23:391-436.

336.Mendelson WB. Neurotransmitters and sleep. J Clin Psychiatry. 2001;62 Suppl 10:5-8.

337.Monnier M, Gaillard JM. Biochemical regulation of sleep. Experientia. 1980;36:21-24.

338.Nelson SR, Walaszek EJ. Pharmacology of the central nervous system. Prog Neurol Psychiatry. 1969;24:131-152.

339.Otter HP, Baust W. Experiments on cholinergic mechanisms for the control of tonic and phasic components of REM sleep. Electroencephalogr Clin Neurophysiol. 1970;29:218.

340.Perry E, Walker M, Grace J et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273-280.

341.Richter D. Biochemical changes during sleep. Verh Dtsch Ges Inn Med. 1965;71:819-826.

342.Rojas-Ramirez JA, Drucker-Colin RR. Sleep induced by spinal cord cholinergic stimulation. Int J Neurosci. 1973;5:215-221.

343.Saito Y. The circadian rhythm of brain acetylcholine levels and motor activity in the rat. Life Sci I. 1971;10:735-744.

344.Shiromani PJ, Kilduff TS, Bloom FE et al. Cholinergically induced REM sleep triggers Fos-like immunoreactivity in dorsolateral pontine regions associated with REM sleep. Brain Res. 1992;580:351-357.

345.Sitaram N, Nurnberger JI, Jr., Gershon ES et al. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder. Am J Psychiatry. 1982;139:571-576.

346.Sitaram N, Wyatt RJ, Dawson S et al. REM sleep induction by physostigmine infusion during sleep. Science. 1976;191:1281-1283.

347.Steriade M. Cholinergic blockage of network- and intrinsically generated slow oscillations promotes waking and REM sleep activity patterns in thalamic and cortical neurons. Prog Brain Res. 1993;98:345-355.

348.Szymusiak R, Danowski J, McGinty D. REM sleep-suppressing effects of atropine in cats vary with environmental temperature. Brain Res. 1994;636:115-118.

349.Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol. 2001;280:R598-R601.

350.Velazquez-Moctezuma J, Shiromani PJ, Gillin JC. Acetylcholine and acetylcholine receptor subtypes in REM sleep generation. Prog Brain Res. 1990;84:407-413.

351.Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol. 1991;37:475-524.

352.Borsook D, Richardson GS, Moore-Ede MC et al. GABA and circadian timekeeping: implications for manic-depression and sleep disorders. Med Hypotheses. 1986;19:185-198.

353.Holmes CJ, Jones BE. Importance of cholinergic, GABAergic, serotonergic and other neurons in the medial medullary reticular formation for sleep-wake states studied by cytotoxic lesions in the cat. Neuroscience. 1994;62:1179-1200.

354.Lemoine P, Allain H. Induction of sleep. Sleep. 1996;19:S1-S6.

355.Mallick BN, Kaur S, Saxena RN. Interactions between cholinergic and GABAergic neurotransmitters in and around the locus coeruleus for the induction and maintenance of rapid eye movement sleep in rats. Neuroscience. 2001;104:467-485.

356.Maloney KJ, Mainville L, Jones BE. c-Fos expression in GABAergic, serotonergic, and other neurons of the pontomedullary reticular formation and raphe after paradoxical sleep deprivation and recovery. J Neurosci. 2000;20:4669-4679.

357.Nitz D, Siegel J. GABA release in the dorsal raphe nucleus: role in the control of REM sleep. Am J Physiol. 1997;273:R451-R455.

358.Nitz D, Siegel JM. GABA release in the locus coeruleus as a function of sleep/wake state. Neuroscience. 1997;78:795-801.

359.Nitz D, Siegel JM. GABA release in posterior hypothalamus across sleep-wake cycle. Am J Physiol. 1996;271:R1707-R1712.

360.Pavel S, Eisner C. A GABAergic habenulo-raphe pathway mediates both serotoninergic and hypnogenic effects of vasotocin in cats. Brain Res Bull. 1984;13:623-627.

361.Stahmer SD. Pharmacodynamics of benzodiazepines. S Afr Med J. 1985;Suppl:14-22.

362.Stock G. [Mechanisms of falling asleep. (Possibility of drug therapy in sleep disorders--participation of monoaminergic and gabaergic systems in the sleep-waking cycle)]. Arzneimittelforschung. 1981;Suppl 27:15-17.

363.Torterolo P, Yamuy J, Sampogna S et al. GABAergic neurons of the cat dorsal raphe nucleus express c-fos during carbachol-induced active sleep. Brain Res. 2000;884:68-76.

364.Xi MC, Morales FR, Chase MH. Evidence that wakefulness and REM sleep are controlled by a GABAergic pontine mechanism. J Neurophysiol. 1999;82:2015-2019.

365.Katzung B. Basic and Clinical Pharmacology. 7th ed. Stamford, Conn: Appleton and Lange, 1998.

366.DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25-58.

367.Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? Med Hypotheses. 2000;55:491-493.

368.Dinsmore ST. Treatment options for Alzheimer's disease. J Am Osteopath Assoc. 1999;99:S6-S8.

369.Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. J Geriatr Psychiatry Neurol. 1998;11:163-173.

370.Kristofikova Z, Klaschka J. In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus. Dement Geriatr Cogn Disord. 1997;8:43-48.

371.Ramassamy C, Clostre F, Christen Y et al. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol. 1990;42:785-789.

372.The role of excitatory amino acids in the actions of abused drugs. NIDA Res Monogr. 1994;140:65-68.

373.Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan- restricted rats during development. Int J Dev Neurosci. 2002;20:47-54.

374.Arrigoni E, Rainnie DG, McCarley RW et al. Adenosine-mediated presynaptic modulation of glutamatergic transmission in the laterodorsal tegmentum. J Neurosci. 2001;21:1076-1085.

375.Barbeito L, Cheramy A, Godeheu G et al. Glutamate Receptors of a Quisqualate-Kainate Subtype are Involved in the Presynaptic Regulation of Dopamine Release in the Cat Caudate Nucleus in vivo. Eur J Neurosci. 1990;2:304-311.

376.Belenikin MS, Baskin II, Palyulin VA et al. A new binding mode of competitive antagonists to metabotropic glutamate receptors exemplified by the mGluR1-receptor antagonist AIDA (RS- aminoindan-1,5-dicarboxylic acid). Dokl Biochem Biophys. 2002;384:131-135.

377.Breysse N, Baunez C, Spooren W et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci. 2002;22:5669-5678.

378.Car H, Oksztel R, Nadlewska A et al. NMDA receptor antagonists change behavioral activity of rats treated with (S)-4CPG. Pol J Pharmacol. 2001;53:331-339.

379.Chiang AS, Pszczolkowski MA, Liu HP et al. Ionotropic glutamate receptors mediate juvenile hormone synthesis in the cockroach, Diploptera punctata. Insect Biochem Mol Biol. 2002;32:669-678.

380.Dhami GK, Anborgh PH, Dale LB et al. Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. J Biol Chem. 2002;277:25266-25272.

381.Diaz-Cabiale Z, Vivo M, del Arco A et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett. 2002;324:154-158.

382.Doi A, Ishibashi H, Jinno S et al. Presynaptic inhibition of GABAergic miniature currents by metabotropic glutamate receptor in the rat CNS.

383.Fendt M, Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci. 2002;15:1535-1541.

384.Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther. 2002;28 Suppl 1:101-121.

385.Grosshans DR, Clayton DA, Coultrap SJ et al. Analysis of glutamate receptor surface expression in acute hippocampal slices. Sci STKE. 2002;2002:L8.

386.Holscher C. Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1. Pharmacol Biochem Behav. 2002;73:307-316.

387.Huemmeke M, Eysel UT, Mittmann T. Metabotropic glutamate receptors mediate expression of LTP in slices of rat visual cortex. Eur J Neurosci. 2002;15:1641-1645.

388.Karlsson U, Sjodin J, Angeby MK et al. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation. Neuroscience. 2002;112:861-868.

389.Katsurabayashi S, Kubota H, Wang ZM et al. cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons. J Neurophysiol. 2001;85:332-340.

390.Lee RK, Jimenez J, Cox AJ et al. Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Ann N Y Acad Sci. 1996;777:338-343.

391.Leinekugel X, Khazipov R, Cannon R et al. Correlated bursts of activity in the neonatal hippocampus in vivo. Science. 2002;296:2049-2052.

392.Li W, Trexler EB, Massey SC. Glutamate receptors at rod bipolar ribbon synapses in the rabbit retina. J Comp Neurol. 2002;448:230-248.

393.Mao L, Wang JQ. Glutamate Cascade to cAMP Response Element-Binding Protein Phosphorylation in Cultured Striatal Neurons through Calcium-Coupled Group I Metabotropic Glutamate Receptors. Mol Pharmacol. 2002;62:473-484.

394.Martin-Ruiz R, Puig MV, Celada P et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001;21:9856-9866.

395.Meeker RB. Metabotropic and NMDA glutamate receptor interactions with osmotic stimuli in supraoptic neurons. Pharmacol Biochem Behav. 2002;73:475-484.

396.Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002;51:775-787.

397.Neugebauer V. Metabotropic glutamate receptors - important modulators of nociception and pain behavior. Pain. 2002;98:1-8.

398.Pisani A, Bonsi P, Catania MV et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci. 2002;22:6176-6185.

399.Schoepp DD. Metabotropic glutamate receptors. Pharmacol Biochem Behav. 2002;73:285-286.

400.Sevoz-Couche C, Maisonneuve B, Hamon M et al. Glutamate and NO mediation of the pressor response to 5-HT3 receptor stimulation in the nucleus tractus solitarii. Neuroreport. 2002;13:837-841.

401.Suchak SK, Baloyianni NV, Perkinton MS et al. The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J Neurochem. 2003;84:522-532.

402.Ulus IH, Wurtman RJ. Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. J Pharmacol Exp Ther. 1997;281:149-154.

403.Wang G, Ding S, Yunokuchi K. Glutamate-induced increases in intracellular Ca2+ in cultured rat neocortical neurons. Neuroreport. 2002;13:1051-1056.

404.Chen JF, Moratalla R, Impagnatiello F et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:1970-1975.

405.Chen JF, Xu K, Petzer JP et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21:RC143.

406.Conlay LA, Conant JA, deBros F et al. Caffeine alters plasma adenosine levels. Nature. 1997;389:136.

407.Conlay LA, Evoniuk G, Wurtman RJ. Endogenous adenosine and hemorrhagic shock: effects of caffeine administration or caffeine withdrawal. Proc Natl Acad Sci U S A. 1988;85:4483-4485.

408.Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism. 1992;41:1233-1241.

409.Dulloo AG, Seydoux J, Girardier L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int J Obes. 1991;15:317-326.

410.Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31-55.

411.Evoniuk G, von Borstel RW, Wurtman RJ. Antagonism of the cardiovascular effects of adenosine by caffeine or 8- (p-sulfophenyl)theophylline. J Pharmacol Exp Ther. 1987;240:428-432.

412.Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002;58:1154-1160.

413.Tofovic SP, Zacharia L, Carcillo JA et al. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Shock. 2001;16:196-202.

414.von Borstel RW, Renshaw AA, Wurtman RJ. Adenosine strongly potentiates pressor responses to nicotine in rats. Proc Natl Acad Sci U S A. 1984;81:5599-5603.

415.Barcz E, Sommer E, Janik P et al. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol Rep. 2000;7:1285-1291.

416.Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism. 1992;41:1233-1241.

417.Richter A, Hamann M. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. Br J Pharmacol. 2001;134:343-352.

418.Satoh A, Satoh K, Masamune A et al. Activation of adenosine A2a receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis. Pancreas. 2002;24:75-82.

419.Dulloo AG, Seydoux J, Girardier L et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord. 2000;24:252-258.

420.Luceri C, Caderni G, Sanna A et al. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione- related enzymes in azoxymethane-induced f344 rat colon tumors. J Nutr. 2002;132:1376-1379.

421.Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem. 2001;49:3438-3442.

422.Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:2073S-2085S.

423.Adrien J, Bourgoin S, Hamon M. Midbrain raphe lesion in the newborn rat I. Neurophysiological aspects of sleep. Brain Res. 1977;127:99-110.

424.Barratt ES, Adams PM, Poffenbarger PL et al. Effects of rapid depletion of phenylalanine and tyrosine on sleep and behavior. Pharmacol Biochem Behav. 1976;5:47-53.

425.Bhatti T, Gillin JC, Seifritz E et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry. 1998;43:52-59.

426.Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. Experientia. 1983;39:551-558.

427.Bouhuys AL, Van Den Hoofdakker RH. Effects of midbrain raphe destruction on sleep and locomotor activity in rats. Physiol Behav. 1977;19:535-541.

428.Bronzino JD, Morgane PJ, Stern WC. EEG synchronization following application of serotonin to area postrema. Am J Physiol. 1972;223:376-383.

429.Brus R, Herman ZS, Jamrozik Z et al. Action of biogenic amines injected intracerebrally on duration of hexobarbital-induced sleep in rats. Arch Immunol Ther Exp (Warsz ). 1975;23:459-463.

430.Bryson G. Biogenic amines in normal and abnormal behavioral states. Clin Chem. 1971;17:5-26.

431.Cape EG, Jones BE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci. 1998;18:2653-2666.

432.Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. Clin Ter. 1979;91:3-10.

433.Carlsson A. Interaction between dopaminergic and serotonergic systems. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:616A-617A.

434.Cespuglio R, Burlet S, Faradji-Prevautel H. 5-Hydroxyindoles compounds and nitric oxide voltammetric detection in the rat brain: changes occurring throughout the sleep-wake cycle. J Neural Transm. 1998;105:205-215.

435.Chuman MA. The neurological basis of sleep. Heart Lung. 1983;12:177-182.

436.Curzon G. The role and control of brain 5-hydroxytryptamine. Acta Neurol (Napoli). 1977;32:121-131.

437.Drucker-Colin RR, Rojas-Ramirez JA. New approaches to the study of the neurochemical basis of sleep and wakefulness. Adv Psychobiol. 1976;3:1-34.

438.Dugovic C, Leysen JE, Wauquier A. Melatonin modulates the sensitivity of 5-hydroxytryptamine-2 receptor-mediated sleep-wakefulness regulation in the rat. Neurosci Lett. 1989;104:320-325.

439.Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. I. Relation to postsynaptic serotonergic stimulation. J Pharmacol Exp Ther. 1983;225:667-674.

440.Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. II. Evidence against the involvement of presynaptic serotonergic mechanism. J Pharmacol Exp Ther. 1983;225:675-681.

441.Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. Nature. 2000;404:992-995.

442.Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. Trends Neurosci. 2001;24:237-243.

443.Grazia dS, Imeri L, De Matteo W et al. Sleep regulation: interactions among cytokines and classical neurotransmitters. Adv Neuroimmunol. 1995;5:189-200.

444.Guha M, Biswas S, Poddar MK. Possible involvement of central cholinergic-serotonergic interaction in natural sleep. Methods Find Exp Clin Pharmacol. 1988;10:243-245.

445.Hartmann E. L-tryptophan: a rational hypnotic with clinical potential. Am J Psychiatry. 1977;134:366-370.

446.Hill SY, Reyes RB. Effects of L-tryptophan and ethanol on sleep parameters in the rat. Psychopharmacology (Berl). 1978;58:229-233.

447.Hirsh K. Central nervous system pharmacology of the dietary methylxanthines. Prog Clin Biol Res. 1984;158:235-301.

448.Holman RB, Elliott GR, Barchas JD. Neuroregulators and sleep mechanisms. Annu Rev Med. 1975;26:499-520.

449.Horner RL. Is there a rationale in modulating brainstem neurons in obstructive sleep apnea and is it clinically relevant? Sleep. 2000;23 Suppl 4:S179-S181.

450.Ingram DK, London ED, Reynolds MA. Circadian rhythmicity and sleep: effects of aging in laboratory animals. Neurobiol Aging. 1982;3:287-297.

451.Iwakiri H, Matsuyama K, Mori S. Extracellular levels of serotonin in the medial pontine reticular formation in relation to sleep-wake cycle in cats: a microdialysis study. Neurosci Res. 1993;18:157-170.

452.Jouvet M. [Neuromediators and hypnogenic factors]. Rev Neurol (Paris). 1984;140:389-400.

453.Jouvet M. Sleep and serotonin: an unfinished story. Neuropsychopharmacology. 1999;21:24S-27S.

454.Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. Experientia. 1984;40:309-338.

455.Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. Nippon Rinsho. 1998;56:318-326.

456.Leathwood PD. Tryptophan availability and serotonin synthesis. Proc Nutr Soc. 1987;46:143-156.

457.Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. II. Time course of dorsal raphe discharge, PGO waves, and behavioral states. Arch Ital Biol. 1987;126:1-28.

458.Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. Brain Res. 1989;494:294-306.

459.Masek K, Kadlec O. Sleep factor, muramyl peptides, and the serotoninergic system. Lancet. 1983;1:1277.

460.Moja EA, Mendelson WB, Stoff DM et al. Reduction of REM sleep by a tryptophan-free amino acid diet. Life Sci. 1979;24:1467-1470.

461.Monnier M, Gaillard JM. Biochemical regulation of sleep. Experientia. 1980;36:21-24.

462.Nicholson AN, Pascoe PA. 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology. 1986;25:1079-1083.

463.Pecknold JC, Luthe L. Sleep studies and neurochemical correlates in panic disorder and agoraphobia. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:753-758.

464.Pradhan SN, Dutta SN. Central cholinergic mechanism and behavior. Int Rev Neurobiol. 1971;14:173-231.

465.Puizillout JJ, Gaudin-Chazal G, Sayadi A et al. Serotoninergic mechanisms and sleep. J Physiol (Paris). 1981;77:415-424.

466.Sallanon M, Janin M, Buda C et al. Serotoninergic mechanisms and sleep rebound. Brain Res. 1983;268:95-104.

467.Schulz H. [Sleep and wake-cycle as circadian rhythm (author's transl)]. Wien Klin Wochenschr Suppl. 1979;106:3-5.

468.Seifritz E. Contribution of sleep physiology to depressive pathophysiology. Neuropsychopharmacology. 2001;25:S85-S88.

469.Toru M. Proceedings: Brain monoamine metabolism and sleep. Electroencephalogr Clin Neurophysiol. 1975;39:542.

470.Touret M, Sarda N, Gharib A et al. The role of 5-hydroxytryptophan (5-HTP) in the regulation of the sleep/wake cycle in parachlorophenylalanine (p-CPA) pretreated rat: a multiple approach study. Exp Brain Res. 1991;86:117-124.

471.Turek FW, Dugovic C, Zee PC. Current understanding of the circadian clock and the clinical implications for neurological disorders. Arch Neurol. 2001;58:1781-1787.

472.Valatx JL. [Sleep: current data in 1990]. Presse Med. 1990;19:1827-1831.

473.Vasilescu E. Sleep induced by intraventricular administration of serotonin and melatonin in tortoise (Emys orbicularis). Neurol Psychiatr (Bucur ). 1982;20:125-129.

474.Wojcik WJ, Fornal C, Radulovacki M. Effect of tryptophan on sleep in the rat. Neuropharmacology. 1980;19:163-167.

475.Wyatt RJ, Chase TN, Kupfer DJ et al. Brain catecholamines and human sleep. Nature. 1971;233:63-65.

476.Yogman MW, Zeisel SH. Diet and sleep patterns in newborn infants. N Engl J Med. 1983;309:1147-1149.

477.Yogman MW, Zeisel SH. Nutrients, neurotransmitters and infant behavior. Am J Clin Nutr. 1985;42:352-360.

478.Allen RP, McCann UD, Ricaurte GA. Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep. 1993;16:560-564.

479.Arito H, Tsuruta H, Nakagaki K et al. Partial insomnia, hyperactivity and hyperdipsia induced by repeated administration of toluene in rats: their relation to brain monoamine metabolism. Toxicology. 1985;37:99-110.

480.Bell C, Wilson S, Nutt DJ. Pindolol augmentation of sertraline in resistant depression and its effect on sleep. J Psychopharmacol. 1998;12:105-107.

481.Bhatti T, Gillin JC, Seifritz E et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry. 1998;43:52-59.

482.Billiard M, Besset A, Renaud B et al. [Insomnia in bismuth encephalopathy (author's transl)]. Rev Electroencephalogr Neurophysiol Clin. 1977;7:147-152.

483.Birmaher B, Heydl P. Biological studies in depressed children and adolescents. Int J Neuropsychopharmacol. 2001;4:149-157.

484.Bjorvatn B, Ursin R. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats. Behav Brain Res. 1990;40:239-246.

485.Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. Experientia. 1983;39:551-558.

486.Borbely AA, Neuhaus HU, Tobler I. Effect of p-chlorophenylalanine and tryptophan on sleep, EEG and motor activity in the rat. Behav Brain Res. 1981;2:1-22.

487.Brentegani LG, Brentegani MR, Lico MC. Dental pain and sleep. Experimental study on guinea pigs (Cavia porcellus). Braz Dent J. 1992;2:129-133.

488.Bronzino JD. Quantitative analysis of the EEG--general concepts and animal studies. IEEE Trans Biomed Eng. 1984;31:850-856.

489.Brooks DC, Gershon MD. Amine repletion in the reserpinized cat: effect upon PGO waves and REM sleep. Electroencephalogr Clin Neurophysiol. 1977;42:35-47.

490.Buckton G, Zibrowski EM, Vanderwolf CH. Effects of cyclazocine and scopolamine on swim-to-platform performance in rats. Brain Res. 2001;922:229-233.

491.Cape EG, Jones BE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci. 1998;18:2653-2666.

492.Chuman MA. The neurological basis of sleep. Heart Lung. 1983;12:177-182.

493.Clancy JJ, Caldwell DF, Oberleas D et al. Effect of a chronic tryptophan dietary deficiency on the rat's sleep-wake cycle. Brain Res Bull. 1978;3:83-87.

494.Deguchi T, Sinha AK, Dement WC et al. Enzyme activity in sleep and sleep deprivation. Pharmacol Biochem Behav. 1975;3:957-960.

495.Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. J Neurosurg. 1985;63:321-341.

496.Fornal C, Wojcik WJ, Radulovacki M et al. Hypnotic effect of tryptophan analog in rats. Pharmacol Biochem Behav. 1979;11:319-323.

497.Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. II. Evidence against the involvement of presynaptic serotonergic mechanism. J Pharmacol Exp Ther. 1983;225:675-681.

498.Gershon MD, Brooks DC. Monoamine oxidase inhibition and the induction of ponto-geniculo-occipital wave activity by reserpine in the cat. J Pharmacol Exp Ther. 1976;197:556-566.

499.Gervasoni D, Peyron C, Rampon C et al. Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. J Neurosci. 2000;20:4217-4225.

500.Gromov LA, Pishel' VI. [The serotoninergic mechanism and the experimental therapy of sleep disorders in desynchronization]. Patol Fiziol Eksp Ter. 1990;22-23.

501.Guilleminault C, Baker TL. Sleep and electroencephalography: points of interest and points of controversy. J Clin Neurophysiol. 1984;1:275-291.

502.Gupta MA. Is chronic pain a variant of depressive illness? A critical review. Can J Psychiatry. 1986;31:241-248.

503.Guzman-Marin R, Alam MN, Mihailescu S et al. Subcutaneous administration of nicotine changes dorsal raphe serotonergic neurons discharge rate during REM sleep. Brain Res. 2001;888:321-325.

504.Haranath PS, Venkatakrishna-Bhatt H. Sleep induced by drugs injected into the inferior horn of the lateral cerebral ventricle in dogs. Br J Pharmacol. 1977;59:231-236.

505.Haranath PS, Indira G, Krishnamurthy A. Effects of cholinomimetic drugs and their antagonists injected into vertebral artery of unanaesthetized dogs. Pharmacol Biochem Behav. 1977;6:259-263.

506.Herdman JR, Cowen PJ, Campling GM et al. Effect of lofepramine on 5-HT function and sleep. J Affect Disord. 1993;29:63-72.

507.Hilaire-Kafi S, Gaillard JM. Hypnotic action of flunitrazepam in the rat: does 5-HT mechanism play a role? Neuropharmacology. 1988;27:1227-1230.

508.Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. Curr Opin Neurobiol. 1992;2:759-763.

509.Imeri L, De Simoni MG, Giglio R et al. Changes in the serotonergic system during the sleep-wake cycle: simultaneous polygraphic and voltammetric recordings in hypothalamus using a telemetry system. Neuroscience. 1994;58:353-358.

510.Imeri L, Bianchi S, Mancia M. Muramyl dipeptide and IL-1 effects on sleep and brain temperature after inhibition of serotonin synthesis. Am J Physiol. 1997;273:R1663-R1668.

511.Imeri L, Gemma C, De Simoni MG et al. Hypothalamic serotonergic activity correlates better with brain temperature than with sleep-wake cycle and muscle tone in rats. Neuroscience. 1999;89:1241-1246.

512.Imeri L, Mancia M, Bianchi S et al. 5-Hydroxytryptophan, but not L-tryptophan, alters sleep and brain temperature in rats. Neuroscience. 2000;95:445-452.

513.Iwakiri H, Matsuyama K, Mori S. Extracellular levels of serotonin in the medial pontine reticular formation in relation to sleep-wake cycle in cats: a microdialysis study. Neurosci Res. 1993;18:157-170.

514.Jaramillo J. Pharmacological studies on tandamine hydrochloride, a potential heterocyclic antidepressant. Naunyn Schmiedebergs Arch Pharmacol. 1978;302:107-113.

515.Kiianmaa K, Fuxe K. The effects of 5,7-dihydroxytryptamine-induced lesions of the ascending 5-hydroxytryptamine pathways on the sleep wakefulness cycle. Brain Res. 1977;131:287-301.

516.Kilduff TS, Krilowicz B, Milsom WK et al. Sleep and mammalian hibernation: homologous adaptations and homologous processes? Sleep. 1993;16:372-386.

517.Kleinlogel H, Burki HR. Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine on EEG sleep and waking stages in the rat. Neuropsychobiology. 1987;17:206-212.

518.Kodama T, Honda Y, Nakao M et al. Relative power contributions of unit discharges simultaneously recorded in the mesencephalic reticular formation. Psychiatry Clin Neurosci. 2000;54:265-267.

519.Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. Experientia. 1984;40:309-338.

520.Koella WP. [Biochemistry and pharmacology of vigilance: role of neurotransmitters within the framework of vigilance control]. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb. 1984;15:180-189.

521.Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28 Suppl:55-63.

522.Kowatch RA, Schnoll SS, Knisely JS et al. Electroencephalographic sleep and mood during cocaine withdrawal. J Addict Dis. 1992;11:21-45.

523.Koyama Y, Jodo E, Kayama Y. Sensory responsiveness of "broad-spike" neurons in the laterodorsal tegmental nucleus, locus coeruleus and dorsal raphe of awake rats: implications for cholinergic and monoaminergic neuron-specific responses. Neuroscience. 1994;63:1021-1031.

524.Kubow S, Anderson GH, Blendis LM et al. 3-methylbutanal metabolism in the adult rat. Clin Sci (Lond). 1981;61:451-455.

525.Receptor physiology and hormone secretion in affective illness. Psychopharmacol Bull. 1983;19:479-495.

526.Bovier P, Dick P. [Current status, perspectives and limitations of serotonin precursors]. Rev Med Suisse Romande. 1990;110:885-890.

527.Cervera S. [Differential features of SSRIs]. Rev Med Univ Navarra. 1997;41:245-257.

528.Curzon G. The role and control of brain 5-hydroxytryptamine. Acta Neurol (Napoli). 1977;32:121-131.

529.Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiol Clin. 2001;31:18-33.

530.Doogan DP. Fluvoxamine as an antidepressant drug. Neuropharmacology. 1980;19:1215-1216.

531.Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. J Neurosurg. 1985;63:321-341.

532.Gilbert JC. Psychological medicine. Drugs used in psychological medicine: pharmacological basis of treatment. Br Med J. 1976;1:882-884.

533.Kumar AM, Berger JR, Eisdorfer C et al. Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology. 2001;44:13-18.

534.Maier J. [Psychotropic drugs for the aged. Drug therapy in geriatric psychotic disorders]. ZFA. 1981;36:323-330.

535.Mitsunobu K. [Depression and serotonin metabolism]. Nippon Rinsho. 1978;36:83-89.

536.Moller SE. [Tryptophan. Peripheral regulation of central function]. Ugeskr Laeger. 1979;141:458-461.

537.Moore P, Landolt HP, Seifritz E et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 2000;23:601-622.

538.Murphy DL, Aulakh CS, Garrick NA. How antidepressants work: cautionary conclusions based on clinical and laboratory studies of the longer-term consequences of antidepressant drug treatment. Ciba Found Symp. 1986;123:106-125.

539.Perry TL, Wright JM, Berry K et al. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. Neurology. 1990;40:1882-1887.

540.Poitou P, Boulu R. [Psychopharmacology of tryptophan (author's transl)]. Pathol Biol (Paris). 1977;25:565-571.

541.Post RM, Kotin J, Goodwin FK. Effects of sleep deprivation on mood and central amine metabolism in depressed patients. Arch Gen Psychiatry. 1976;33:627-632.

542.Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12 Suppl 1:2-19.

543.Russell IJ, Vipraio GA, Morgan WW et al. Is there a metabolic basis for the fibrositis syndrome? Am J Med. 1986;81:50-54.

544.Silberstein SD. Comprehensive management of headache and depression. Cephalalgia. 1998;18 Suppl 21:50-55.

545.Villar MJ. [New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus]. Acta Psiquiatr Psicol Am Lat. 1994;40:293-300.

546.Whitaker-Azmitia PM. Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989. New Biol. 1989;1:145-148.

547.Wilke WS, Mackenzie AH. Proposed pathogenesis of fibrositis. Cleve Clin Q. 1985;52:147-154.

548.Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res. 1995;3 Suppl 4:477S-480S.

549.Receptor physiology and hormone secretion in affective illness. Psychopharmacol Bull. 1983;19:479-495.

550.Bovier P, Dick P. [Current status, perspectives and limitations of serotonin precursors]. Rev Med Suisse Romande. 1990;110:885-890.

551.Cervera S. [Differential features of SSRIs]. Rev Med Univ Navarra. 1997;41:245-257.

552.Curzon G. The role and control of brain 5-hydroxytryptamine. Acta Neurol (Napoli). 1977;32:121-131.

553.Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiol Clin. 2001;31:18-33.

554.Doogan DP. Fluvoxamine as an antidepressant drug. Neuropharmacology. 1980;19:1215-1216.

555.Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. J Neurosurg. 1985;63:321-341.

556.Gilbert JC. Psychological medicine. Drugs used in psychological medicine: pharmacological basis of treatment. Br Med J. 1976;1:882-884.

557.Moller SE. [Tryptophan. Peripheral regulation of central function]. Ugeskr Laeger. 1979;141:458-461.

558.Moore P, Landolt HP, Seifritz E et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 2000;23:601-622.

559.Perry TL, Wright JM, Berry K et al. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. Neurology. 1990;40:1882-1887.

560.Poitou P, Boulu R. [Psychopharmacology of tryptophan (author's transl)]. Pathol Biol (Paris). 1977;25:565-571.

561.Post RM, Kotin J, Goodwin FK. Effects of sleep deprivation on mood and central amine metabolism in depressed patients. Arch Gen Psychiatry. 1976;33:627-632.

562.Russell IJ, Vipraio GA, Morgan WW et al. Is there a metabolic basis for the fibrositis syndrome? Am J Med. 1986;81:50-54.

563.Silberstein SD. Comprehensive management of headache and depression. Cephalalgia. 1998;18 Suppl 21:50-55.

564.Villar MJ. [New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus]. Acta Psiquiatr Psicol Am Lat. 1994;40:293-300.

565.Whitaker-Azmitia PM. Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989. New Biol. 1989;1:145-148.

566.Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res. 1995;3 Suppl 4:477S-480S.

567.Behan M, Zabka AG, Mitchell GS. Age and gender effects on serotonin-dependent plasticity in respiratory motor control. Respir Physiolo Neurobiol. 2002;131:65-77.

568.Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. Chest. 1999;115:1397-1401.

569.Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. Neurophysiol Clin. 2001;31:18-33.

570.Grunstein RR, Hedner J, Grote L. Treatment options for sleep apnoea. Drugs. 2001;61:237-251.

571.Hilaire G, Morin D, Lajard AM et al. Changes in serotonin metabolism may elicit obstructive apnoea in the newborn rat. J Physiol. 1993;466:367-381.

572.Horner RL. Is there a rationale in modulating brainstem neurons in obstructive sleep apnea and is it clinically relevant? Sleep. 2000;23 Suppl 4:S179-S181.

573.Hudgel DW. Pharmacologic treatment of obstructive sleep apnea. J Lab Clin Med. 1995;126:13-18.

574.Hudgel DW, Gordon EA, Meltzer HY. Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea. Am J Respir Crit Care Med. 1995;152:186-192.

575.Hudgel DW, Gordon EA. Serotonin-induced cortisol release in CPAP-treated obstructive sleep apnea patients. Chest. 1997;111:632-638.

576.Kraiczi H, Hedner J, Dahlof P et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep. 1999;22:61-67.

577.Morin D, Di Pasquale E, Hilaire G et al. Possible involvement of serotonin in obstructive apnea of the newborn. Biol Neonate. 1994;65:176-181.

578.Okabe S. [Future direction of therapies for sleep related breathing disorders]. Nippon Rinsho. 2000;58:1693-1697.

579.Plantamura A, Steinbauer J, Eisinger J. [Sleep apnea and fibromyalgia: the absence of correlation does not indicate an exclusive central hypothesis]. Rev Med Interne. 1995;16:662-665.

580.Radulovacki M, Trbovic SM, Carley DW. Serotonin 5-HT3-receptor antagonist GR 38032F suppresses sleep apneas in rats. Sleep. 1998;21:131-136.

581.Saito Y, Ito M, Ozawa Y et al. Changes of neurotransmitters in the brainstem of patients with respiratory-pattern disorders during childhood. Neuropediatrics. 1999;30:133-140.

582.Schmidt HS. L-tryptophan in the treatment of impaired respiration in sleep. Bull Eur Physiopathol Respir. 1983;19:625-629.

583.Sunderram J, Parisi RA, Strobel RJ. Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2000;162:925-929.

584.Veasey SC, Panckeri KA, Hoffman EA et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. Am J Respir Crit Care Med. 1996;153:776-786.

585.Veasey SC. Serotonin. Culprit or promising therapy for obstructive sleep apnea? Am J Respir Crit Care Med. 2001;163:1045-1047.

586.Veasey SC. Pharmacotherapies for obstructive sleep apnea: how close are we? Curr Opin Pulm Med. 2001;7:399-403.

587.Muzur A, Pace-Schott EF, Hobson JA. The prefrontal cortex in sleep. Trends Cogn Sci. 2002;6:475-481.

588.Sawaguchi T, Franco P, Kato I et al. From physiology to pathology: arousal deficiency theory in sudden infant death syndrome (SIDS)--with reference to apoptosis and neuronal plasticity. Forensic Sci Int. 2002;130 Suppl:S37-S43.

589.Cohen G, Han ZY, Grailhe R et al. beta 2 nicotinic acetylcholine receptor subunit modulates protective responses to stress: A receptor basis for sleep-disordered breathing after nicotine exposure. Proc Natl Acad Sci U S A. 2002;99:13272-13277.

590.Bellingham MC, Ireland MF. Contribution of cholinergic systems to state-dependent modulation of respiratory control. Respir Physiolo Neurobiol. 2002;131:135-144.

591.Joseph V, Pequignot JM, Van Reeth O. Neurochemical perspectives on the control of breathing during sleep. Respir Physiolo Neurobiol. 2002;130:253-263.

592.Eggermann E, Serafin M, Bayer L et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience. 2001;108:177-181.

593.Seifritz E. Contribution of sleep physiology to depressive pathophysiology. Neuropsychopharmacology. 2001;25:S85-S88.

594.Hasselmo ME, Fehlau BP. Differences in time course of ACh and GABA modulation of excitatory synaptic potentials in slices of rat hippocampus. J Neurophysiol. 2001;86:1792-1802.

595.Solms M. Dreaming and REM sleep are controlled by different brain mechanisms. Behav Brain Sci. 2000;23:843-850.

596.Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. Trends Neurosci. 2001;24:237-243.

597.Krahn LE, Black JL, Silber MH. Narcolepsy: new understanding of irresistible sleep. Mayo Clin Proc. 2001;76:185-194.

598.Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol. 2001;280:R598-R601.

599.Cudeiro J, Rivadulla C, Grieve KL. A possible role for nitric oxide at the sleep/wake interface. Sleep. 2000;23:829-835.

600.Kraiczi H, Hedner J, Peker Y et al. Increased vasoconstrictor sensitivity in obstructive sleep apnea. J Appl Physiol. 2000;89:493-498.

601.Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. Nature. 2000;404:992-995.

602.Thomas AJ, Erokwu BO, Yamamoto BK et al. Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacologic suppression of sleep in the neonatal period. Brain Res Dev Brain Res. 2000;120:181-189.

603.Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience. 2000;95:933-952.

604.Hasselmo ME. Neuromodulation: acetylcholine and memory consolidation. Trends Cogn Sci. 1999;3:351-359.

605.Manaye KF, Zweig R, Wu D et al. Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain. Neuroscience. 1999;89:759-770.

606.Kayama Y, Koyama Y. Brainstem neural mechanisms of sleep and wakefulness. Eur Urol. 1998;33 Suppl 3:12-15.

607.Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. Nippon Rinsho. 1998;56:318-326.

608.Capece ML, Lydic R. cAMP and protein kinase A modulate cholinergic rapid eye movement sleep generation. Am J Physiol. 1997;273:R1430-R1440.

609.Steininger TL, Wainer BH, Blakely RD et al. Serotonergic dorsal raphe nucleus projections to the cholinergic and noncholinergic neurons of the pedunculopontine tegmental region: a light and electron microscopic anterograde tracing and immunohistochemical study. J Comp Neurol. 1997;382:302-322.

610.Carlson JT, Rangemark C, Hedner JA. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea. J Hypertens. 1996;14:577-584.

611.Grazia dS, Imeri L, De Matteo W et al. Sleep regulation: interactions among cytokines and classical neurotransmitters. Adv Neuroimmunol. 1995;5:189-200.

612.Williams JA, Comisarow J, Day J et al. State-dependent release of acetylcholine in rat thalamus measured by in vivo microdialysis. J Neurosci. 1994;14:5236-5242.

613.Salin-Pascual RJ, Jimenez-Anguiano A, Duran-Vazquez A et al. Administration of auditory stimulation during recovery after REM sleep deprivation. Sleep. 1994;17:231-235.

614.Szymusiak R, McGinty D, Fairchild MD et al. Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. Brain Res. 1993;629:141-145.

615.Brown DW. Abnormal fluctuations of acetylcholine and serotonin. Med Hypotheses. 1993;40:309-310.

616.Gillin JC, Salin-Pascual R, Velazquez-Moctezuma J et al. Cholinergic receptor subtypes and REM sleep in animals and normal controls. Prog Brain Res. 1993;98:379-387.

617.Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. Curr Opin Neurobiol. 1992;2:759-763.

618.McCormick DA. Neurotransmitter actions in the thalamus and cerebral cortex. J Clin Neurophysiol. 1992;9:212-223.

619.Machowski R, Ansseau M, Charles G et al. Latencies of REM sleep and awakening in major depression: possible indicators of cholinergic activity. Neurophysiol Clin. 1989;19:385-391.

620.Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. Brain Res. 1989;494:294-306.

621.Musa MN. Sleep apnea following withdrawal of amitriptyline. J Clin Pharmacol. 1988;28:1038-1039.

622.Yamamoto J. Roles of cholinergic, dopaminergic, noradrenergic, serotonergic and GABAergic systems in changes of the EEG power spectra and behavioral states in rabbits. Jpn J Pharmacol. 1988;47:123-134.

623.Leong SS, Brown WA. Acetylcholine and affective disorder. J Neural Transm. 1987;70:295-312.

624.Barnes PJ. Circadian variation in airway function. Am J Med. 1985;79:5-9.

625.Gillin JC, Sitaram N. Rapid eye movement (REM) sleep: cholinergic mechanisms. Psychol Med. 1984;14:501-506.

626.Masserano JM, King C. Effects on sleep of acetylcholine perfusion of the locus coeruleus of cats. Neuropharmacology. 1982;21:1163-1167.

627.Sitaram N, Nurnberger JI, Jr., Gershon ES et al. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder. Am J Psychiatry. 1982;139:571-576.

628.Gillin JC, Sitaram N, Mendelson WB. Acetylcholine, sleep, and depression. Hum Neurobiol. 1982;1:211-219.

629.Monnier M, Gaillard JM. Biochemical regulation of sleep. Experientia. 1980;36:21-24.

630.Choi S, Jonak EM, Simpson L et al. Intermittent, chronic fenfluramine administration to rats repeatedly suppresses food intake despite substantial brain serotonin reductions. Brain Res. 2002;928:30-39.

631.Colmenares JL, Wurtman RJ, Fernstrom JD. Effects of ingestion of a carbohydrate-fat meal on the levels and synthesis of 5-hydroxyindoles in various regions of the rat central nervous system. J Neurochem. 1975;25:825-829.

632.Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. Science. 1971;174:1023-1025.

633.Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science. 1972;178:414-416.

634.Fernstrom JD. Dietary precursors and brain neurotransmitter formation. Annu Rev Med. 1981;32:413-425.

635.Fernstrom JD. Effects of the diet on brain function. Acta Astronaut. 1981;8:1035-1042.

636.Fernstrom JD, Fernstrom MH. Monoamines and protein intake: are control mechanisms designed to monitor a threshold intake or a set point? Nutr Rev. 2001;59:S60-S65.

637.Fernstrom JD, Fernstrom MH. Diet, monoamine neurotransmitters and appetite control. Nestle Nutr Workshop Ser Clin Perform Programme. 2001;117-131.

638.Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000;71:1669S-1675S.

639.Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. 1971. Obes Res. 1997;5:377-380.

640.Fernstrom JD. Dietary amino acids and brain function. J Am Diet Assoc. 1994;94:71-77.

641.Fernstrom JD. Tryptophan, serotonin and carbohydrate appetite: will the real carbohydrate craver please stand up! J Nutr. 1988;118:1417-1419.

642.Fernstrom JD. Food-induced changes in brain serotonin synthesis: is there a relationship to appetite for specific macronutrients? Appetite. 1987;8:163-182.

643.Fernstrom JD. Dietary effects on brain serotonin synthesis: relationship to appetite regulation. Am J Clin Nutr. 1985;42:1072-1082.

644.Fernstrom JD. Acute effects of tryptophan and single meals on serotonin synthesis in the rat brain. Adv Biochem Psychopharmacol. 1982;34:85-106.

645.Fernstrom JD. Dietary precursors and brain neurotransmitter formation. Annu Rev Med. 1981;32:413-425.

646.Fernstrom JD, Wurtman RJ, Hammarstrom-Wiklund B et al. Diurnal variations in plasma neutral amino acid concentrations among patients with cirrhosis: effect of dietary protein. Am J Clin Nutr. 1979;32:1923-1933.

647.Fernstrom JD, Faller DV. Neutral amino acids in the brain: changes in response to food ingestion. J Neurochem. 1978;30:1531-1538.

648.Fernstrom JD, Hirsch MJ. Brain serotonin synthesis: reduction in corn-malnourished rats. J Neurochem. 1977;28:877-879.

649.Fernstrom JD. Effects on the diet on brain neurotransmitters. Metabolism. 1977;26:207-223.

650.Fernstrom JD, Munro HN, Wurtman RJ. Brain tryptophan in rats on a high fat diet. Nature. 1977;265:277.

651.Fernstrom JD, Hirsch MJ, Faller DV. Tryptophan concentrations in rat brain. Failure to correlate with free serum tryptophan or its ratio to the sum of other serum neutral amino acids. Biochem J. 1976;160:589-595.

652.Fernstrom JD, Lytle LD. Corn malnutrition, brain serotonin and behavior. Nutr Rev. 1976;34:257-262.

653.Fernstrom JD, Hirsch NJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. Life Sci. 1975;17:455-463.

654.Fernstrom JD, Wurtman RJ. Nutrition and the brain. Sci Am. 1974;230:84-91.

655.Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. Adv Biochem Psychopharmacol. 1974;11:133-142.

656.Fernstrom JD, Wurtman RJ. Effect of chronic corn consumption on serotonin content of rat brain. Nat New Biol. 1971;234:62-64.

657.Fernstrom JD. Effects of the diet and other metabolic phenomena on brain tryptophan uptake and serotonin synthesis. Adv Exp Med Biol. 1991;294:369-376.

658.Fernstrom JD. Tryptophan, serotonin and carbohydrate appetite: will the real carbohydrate craver please stand up! J Nutr. 1988;118:1417-1419.

659.Fernstrom JD, Wurtman RJ. Nutrition and the brain. Sci Am. 1974;230:84-91.

660.Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. Psychother Psychosom. 1993;60:18-32.

661.Ross DS, Fernstrom JD, Wurtman RJ. The role of dietary protein in generating daily rhythms in rat liver tryptophan pyrrolase and tyrosine transaminase. Metabolism. 1973;22:1175-1184.

662.Spedding M, Ouvry C, Millan M et al. Neural control of dieting. Nature. 1996;380:488.

663.Wurtman J. Control of carbohydrate intake in young and adult animals. Int J Obes. 1980;4:310-313.

664.Wurtman JJ, Wurtman RJ. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sci. 1979;24:895-903.

665.Wurtman JJ. The involvement of brain serotonin in excessive carbohydrate snacking by obese carbohydrate cravers. J Am Diet Assoc. 1984;84:1004-1007.

666.Wurtman JJ. Neurotransmitter control of carbohydrate consumption. Ann N Y Acad Sci. 1985;443:145-151.

667.Wurtman JJ. Disorders of food intake. Excessive carbohydrate snack intake among a class of obese people. Ann N Y Acad Sci. 1987;499:197-202.

668.Wurtman JJ. Depression and weight gain: the serotonin connection. J Affect Disord. 1993;29:183-192.

669.Wurtman JJ. Carbohydrate craving, mood changes, and obesity. J Clin Psychiatry. 1988;49 Suppl:37-39.

670.Wurtman JJ. Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. Drugs. 1990;39 Suppl 3:49-52.

671.Wurtman JJ, Wurtman RJ. Studies on the appetite for carbohydrates in rats and humans. J Psychiatr Res. 1982;17:213-221.

672.Wurtman JJ. Carbohydrate cravings: a disorder of food intake and mood. Clin Neuropharmacol. 1988;11 Suppl 1:S139-S145.

673.Wurtman JJ, Fernstrom JD. Free amino acid, protein, and fat contents of breast milk from Guatemalan mothers consuming a corn-based diet. Early Hum Dev. 1979;3:67-77.

674.Wurtman JJ, Moses PL, Wurtman RJ. Prior carbohydrate consumption affects the amount of carbohydrate that rats choose to eat. J Nutr. 1983;113:70-78.

675.Wurtman JJ, Wurtman RJ. Studies on the appetite for carbohydrates in rats and humans. J Psychiatr Res. 1982;17:213-221.

676.Wurtman RJ, Fernstrom JD. Control of brain serotonin by the diet. Adv Neurol. 1974;5:19-29.

677.Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr. 1975;28:638-647.

678.Wurtman RJ. Dietary treatments that affect brain neurotransmitters. Effects on calorie and nutrient intake. Ann N Y Acad Sci. 1987;499:179-190.

679.Wurtman RJ, Wurtman JJ. Do carbohydrates affect food intake via neurotransmitter activity? Appetite. 1988;11 Suppl 1:42-47.

680.Wurtman RJ. Neurotransmitters, control of appetite, and obesity. Curr Concepts Nutr. 1988;16:27-34.

681.Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res. 1995;3 Suppl 4:477S-480S.

682.Wurtman RJ. Nutrients affecting brain composition and behavior. Integr Psychiatry. 1987;5:226-238.

683.Wurtman RJ, Wurtman JJ. Carbohydrate craving, obesity and brain serotonin. Appetite. 1986;7 Suppl:99-103.

684.Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr. 1975;28:638-647.

685.Wurtman RJ, Fernstrom JD. Control of brain serotonin by the diet. Adv Neurol. 1974;5:19-29.

686.Wurtman RJ. Behavioural effects of nutrients. Lancet. 1983;1:1145-1147.

687.Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R et al. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand. 1998;97:374-380.

688.Abou-Saleh MT, Coppen A. The biology of folate in depression: implications for nutritional hypotheses of the psychoses. J Psychiatr Res. 1986;20:91-101.

689.Adams WR, Kiefer SW, Badia-Elder N. Tryptophan deficiency and alcohol consumption in rats as a model for disadvantaged human populations: a preliminary study. Med Anthropol. 1995;16:175-191.

690.Ahveninen J, Kahkonen S, Pennanen S et al. Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans. Neuroimage. 2002;16:1052-1061.

691.Ahveninen J, Jaaskelainen IP, Pennanen S et al. Auditory selective attention modulated by tryptophan depletion in humans. Neurosci Lett. 2003;340:181-184.

692.Akarte NR, Shastri NV. Studies on tryptophan-niacin metabolism in streptozotocin diabetic rats. Diabetes. 1974;23:977-981.

693.Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. Can J Physiol Pharmacol. 1983;61:271-281.

694.Anderson IM, Mortimore C. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion. Adv Exp Med Biol. 1999;467:43-55.

695.Anderson IM, Richell RA, Bradshaw CM. The effect of acute tryptophan depletion on probabilistic choice. J Psychopharmacol. 2003;17:3-7.

696.Angel-Meza AR, Gonzalez-Burgos I, Olvera-Cortes E et al. Chronic tryptophan restriction disrupts grooming chain completion in the rat. Physiol Behav. 1996;59:1099-1102.

697.Angel-Meza AR, Ramirez-Cortes L, Olvera-Cortes E et al. A tryptophan-deficient corn-based diet induces plastic responses in cerebellar cortex cells of rat offspring. Int J Dev Neurosci. 2001;19:447-453.

698.Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan-restricted rats during development. Int J Dev Neurosci. 2002;20:47-54.

699.Anthony TG, Reiter AK, Anthony JC et al. Deficiency of dietary EAA preferentially inhibits mRNA translation of ribosomal proteins in liver of meal-fed rats. Am J Physiol Endocrinol Metab. 2001;281:E430-E439.

700.Aoyagi K, Oomura Y, Shimizu N. Concurrent measurement of serotonin metabolism and single neuron activity changes in the lateral hypothalamus of freely behaving rat. Behav Brain Res. 1992;49:205-212.

701.Aquilio E, Seri S. Effects of dietary changes on muricide activity in adult and young rats. Boll Soc Ital Biol Sper. 1983;59:717-722.

702.Arnulf I, Quintin P, Alvarez JC et al. Mid-morning tryptophan depletion delays REM sleep onset in healthy subjects. Neuropsychopharmacology. 2002;27:843-851.

703.Arrendondo-Vega FX, Santisteban I, Notarangelo LD et al. Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del. Mutations in brief no. 142. Online. Hum Mutat. 1998;11:482.

704.Bach A. Oxaloacetate deficiency in MCT-induced ketogenesis. Arch Int Physiol Biochim. 1978;86:1133-1142.

705.Badawy AA, Morgan CJ, Thomas R. Tryptophan and 5-hydroxytryptamine metabolism in alcoholism. Alcohol Alcohol Suppl. 1993;2:231-235.

706.Badawy AA. Tryptophan metabolism in alcoholism. Adv Exp Med Biol. 1999;467:265-274.

707.Barbui C, Garattini S. Tryptophan and depression. Lancet. 1997;349:1553-1554.

708.Bel N, Artigas F. Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. J Neurochem. 1996;67:669-676.

709.Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry. 2001;178:399-405.

710.Bender DA. Tryptophan and niacin nutrition--is there a problem? Adv Exp Med Biol. 1996;398:565-569.

711.Benkelfat C, Ellenbogen MA, Dean P et al. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry. 1994;51:687-697.

712.Benkelfat C, Seletti B, Palmour RM et al. Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission. Arch Gen Psychiatry. 1995;52:154-156.

713.Benton D, Donohoe RT. The effects of nutrients on mood. Public Health Nutr. 1999;2:403-409.

714.Bjork JM, Dougherty DM, Moeller FG et al. The effects of tryptophan depletion and loading on laboratory aggression in men: time course and a food-restricted control. Psychopharmacology (Berl). 1999;142:24-30.

715.Bjork JM, Dougherty DM, Moeller FG et al. Differential behavioral effects of plasma tryptophan depletion and loading in aggressive and nonaggressive men. Neuropsychopharmacology. 2000;22:357-369.

716.Bleiberg-Daniel F, Le Moullac B, Maire JC et al. Failure of tryptophan deficiency to reduce specifically serum levels of transthyretin or albumin in rats. J Nutr. 1990;120:1610-1616.

717.Booij L, Van der DW, Benkelfat C et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology. 2002;27:852-861.

718.Booth DA, French JA, Wainwright CJ et al. Personal benefits from post-ingestional actions of dietary constituents. Proc Nutr Soc. 1992;51:335-341.

719.Brown CM, Fletcher PJ, Coscina DV. Acute amino acid loads that deplete brain serotonin fail to alter behavior. Pharmacol Biochem Behav. 1998;59:115-121.

720.Burgund ED, Marsolek CJ, Luciana M. Serotonin levels influence patterns of repetition priming. Neuropsychology. 2003;17:161-170.

721.Byerley WF, Risch SC. Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. J Clin Psychopharmacol. 1985;5:191-206.

722.Calapai G, Corica F, Corsonello A et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 1999;104:975-982.

723.Carew LB, Jr., Alster FA, Foss DC et al. Effect of a tryptophan deficiency on thyroid gland, growth hor